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For patients with a variety of end stage lung diseases, lung transplantation has become an 
effective therapy. Chronic allograft rejection occurs in over 50% of patients 5 years post 
transplantation however. Although alloimmune-mediated injury directed against 
endothelial and epithelial structures were traditionally thought to be the major culprit,  
non-alloimmunologic inflammation after bile acid aspiration has been implicated in cystic 
fibrosis (CF) lung injury, after transplantation.  
 
Hypothesis 
Reflux with aspiration of bile acid is present in the lower airways of people with cystic 
fibrosis associated lung injury before and after transplantation. Bile acid challenge would 
cause cytoxicity and release of inflammatory mediators from patient derived primary 
epithelial cells (PBECs), before and after transplantation. 
 
Methods 
PBECs from lung transplantation patients, explanted CF patient cultures and a goblet cell 
line were used to perform proof of concept experiments. In these experiments the effect 
of individual primary and secondary bile acids, porcine pepsin, different patient derived 
gastric juices (whole or filtered and dialysed) samples and an artificial bile acid mixture 
were evaluated. Cell death, Interleukin 8 (IL-8), Interleukin 6 (IL-6) and Granulocyte 
Macrophage Colony Stumulating Factor (GMCSF) production were measured by Titer 





 Epithelial cells can be cultured successfully from the bronchial brushings of lung 
transplant recipient, CF patient explanted lungs and a Goblet cell line.  
In work connected with this study my research group has demonstrated that the lungs of 
people with advanced CF lung disease removed at the time of transplantation contained 
significant levels of bile acids higher than expected based on normal serum levels. I 
therefore tested the effects of bile acids on PBECs from lung transplant and CF patients. 
Challengesof ≥10mol/l was associated with significant cell death. Potentially 
physiological challenges with 1, 5 and 10 mol/l bile acids led to a significant release of 
pro-neutrophilic cytokines from lung transplant PBECs and CF PBECs .The goblet cell 
line HT-29 MTX was resistant to bile acids. 
 
Conclusion 
Aspiration of bile acids in CF lungs before and after transplantation may cause cell 
damage and inflammation. This injury may benefit from medical and surgical treatments 
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Lung transplantation remains the only therapy that can restore selected patients with end 
stage lung disease towards better health (Meachery et al., 2008). In the last two decades 
lung transplantation has become a practical option for end stage lung diseae (Trulock et 
al., 2005). The survival of pulmonary patients at 5 years after lung transplantation is only 
49% however, and is unsatisfactory (Trulock et al., 2005). Long-term patient survival of 
lung transplant recipients is limited by the development of bronchiolitis obliterans 
syndrome (BOS), a clinically measured decrease in allograft function. It is the major 
reason behind the death of adult lung transplant recipients more than one year post 
transplantation (Trulock et al., 2005). Therefore, there is an urgent need to understand the 
mechanisms by which BOS develops. 
Peribronchiolar lymphocytic infiltrates, fibrous scarring and luminal narrowing of the 
small airways are the histological characteristics of the fibroproliferative progression of 
obliterative bronciolitis (OB), which is the histological cause of BOS as defined by Burke 
and colleagues (Burke et al., 1984). The development of OB and thus BOS is thought to 
be influenced by immune and non-immune mediated elements (Girgis et al., 1996, Fisher 
et al., 2002), with overall lung injury contributing to loss of function (Robertson et al., 
2009). The potential link between chronic aspiration and OB after heart-lung 
transplantation was recognised in an early study (Reid et al., 1990). High rates of 
gastroesophageal reflux with resultant aspiration are found after pulmonary 
transplantation (Kirk et al., 1990, Rinaldi et al., 1995). It is thought that, the aspiration of 
gastric components might cause allograft injury and OB directly by cuasing airway 
injury, inflammation and scarring. Aspiration may also cause an increase in acute and 
chronic rejection by exacerbating the alloimmune response (Li et al., 2008). 
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1.1 Literature review  
 
Between January 1995 and June 2009 the major indications leading to lung 
transplantation were, chronic obstructive pulmonary disease (COPD, 26%), idiopathic 
pulmonary fibrosis (IPF, 15%), cystic fibrosis (CF, 26%), α1-anti-trypsin deficiency 
emphysema (7%) and re transplantation (2%) (Figure 1). In the last decade, all the above 
mentioned diseases (except for CF) were considered suitable for single lung 


















Cystic fibrosis (CF) is a common reason for lung transplantation at our centre with 30% 
of the total lung transplantations performed in Newcastle being for CF (Meachery et al., 
2008). Gastro-oesophageal reflux (GOR) is common in CF before and after 
transplantation and may be a particularly important contributor to chronic loss of lung 
function. In this population 31-81% of cystic fibrosis patients show increased acid GOR 
(Ledson et al., 1998, Brodzicki et al., 2002, Scott et al., 1985).  
Figure 1: Indications for adult lung transplantations Alpha-1, α 1-anti-trypsin deficiency 
emphysema, (COPD) Chronic Obstructive Pulmonary Disease, (CF) Cystic fibrosis, (IPF) 
Idiopathic Pulmonary Fibrosis, (IPAH) Idiopathic Pulmonary Arterial Hypertension, (Re-Tx) 
Re-Transplantation, PPH, primary pulmonary hypertension, Other includes: Sarcoidosis 
3.0%, Bronchiectasis 4.4%, Congenital Heart Disease1.3%, LAM 1.2% OB (non-ReTx) 









Alpha-1 COPD CF IPF IPAH Re-Tx Other*
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A reduced pressure of the lower oesophageal sphincter (LOS) (Ledson et al., 1998), 
increased number of transient LOS relaxations (Cucchiara et al., 1991), and postponed 
gastric emptying (Couturier et al., 2004), are some potential reasons for increased gastro-
oesophageal reflux in CF. It has also been argued that increased abdominal-thoracic 
pressure gradients during cough and/or physiotherapy (Ledson et al., 1998) is a possible  
reason behind increased GOR in CF. Measurement of acid GOR has been achieved by 
24h oesophageal pH monitoring in CF patients (Blondeau et al., 2008b). Acidity, volume 
and distribution of gastric contents are three factors which define the damaging potential 
of gastro-oesophageal reflux. A less acidic pH (between 7 and 4) in gastro-oesophageal 
reflux can also be found in the early postprandial period and during the night. The reflux 
make up of GOR could be changed because of the potential adjustability of the volume of 
gastric contents, acidity and concentration of bilio-pancreatic components in CF patients. 
The assessment of all kinds of gastro-oesophageal reflux incidents (acid and weakly 
acidic) (Sifrim et al., 2004) can only be made by the sensitive procedure of combined 
impedance-pH monitoring.  
Heartburn, regurgitation and even oesophagitis are typical GOR findings that could be 
caused by increased GOR in CF patients. A study of CF patients with increased acid GOR 
showed that they have lower levels of lung function than patients without GOR (Navarro 
et al., 2001). This shows the possibility that reflux-induced lung aspiration of gastric 
components is associated with declining lung function. Few studies have shown the 
existence of gastric components in bronchial secretions of CF patients, and any 
correlation between GOR and poor lung function does not mean that there is a causal link 
and does not necessarily show aspiration has occurred. In order to detect CF patients with 
increased GOR and risk of lung aspiration, the detection of gastric indicators in sputum is 
suggested as a surrogate marker for the increased proximal extent of GOR (Potluri et al., 
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2003). This may be a useful relatively non-invasive method e.g compared to 
bronchoscopic based BAL. 
Indicators of gastric contents in bronchoalveolar lavage (BAL) have been shown in 
patients after lung transplant (LTx) including transplanted CF patients during 
bronchoscopy (Stovold et al., 2007). It is known that lung transplant patients transplanted 
because CF have higher levels of pepsin and bile acid in their BAL fluid than other lung 



















1.2 Pepsin as a marker of reflux and aspiration  
Pepsins are acidic proteases with two aspartate residues at the active site (Szecsi, 1992).  
Pepsins have two fold symmetry of two almost identical lobes.  In between the two lobes 
is a central cleft that contains the aspartate residues Asp32 and Asp215.  The mechanism 
of peptide bond hydrolysis involves nucleophilic attack (Power, 1977). 
Pepsin is secreted in the stomach as an inactive zymogen (pepsinogen) which is 
spontaneously activated to pepsin at pHs below 5 with the loss of an N-terminal peptide. 
This results in a metastable molecule (Dee et al., 2006).  The loss of peptide on pHs 
activation and the instability of pepsin explain the irreversible inactivation of pepsin at 
PHs above 7.  Pepsin becomes unfolded at pHs above 7 and although it will refold to 
some extent if the pH is returned to acidic it is misfolded and inactive.  It fails to refold 
correctly due to the loss of absolute symmetry because the N terminal lobe has missing 
peptides compared to the C terminal lobe (Pearson, 2010). 
As a gastric protease pepsin is an important biomarker of reflux and because it retains 
activity up to pH 6.0 an important damaging agent in the aerodigestive tract (Bulmer et 
al., 2010a). 
In addition pepsin can be refluxed into the airways in an active form which will lose 
activity as the pH rises but will not be irreversibly inactivated as the pH will not rise 
much above pH 7.  Therefore it will remain stable and will regain activity as the Ph falls 
with the net reflux/aspiration event. 
Many reflux-related disorders indicate a major role for pepsin (Koufman, 1991). The 
majorty of reflux that leaves the oesophagus is likely to be adove pH4.0 and 
gastroesophageal refluxate, will always contain pepsin (Dunn, 2002, Johnston et al., 
2003, Piper and Fenton, 1965) It is also noteworthy that compared to the  esophageal 
epithelium, the laryngeal epithelium, and in particular the regions that contain respiratory 
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epithelium, are far more sensitive to damage by pepsin in the presence of acidic 
conditions, both strongly and weakly acidic (Johnston et al., 2003, Blondeau et al., 2010, 
Bulmer et al., 2010b). 
One of the potential pathophysiologic mechanisms of reflux (GOR) related to respiratory 
symptoms is microaspiration of gastric contents (Kiljander et al., 2002, Farrell et al., 
2006). Triggered after microaspiration, pulmonary clearance mechanisms and mucus 
bronchial secretion are more involved in the development of symptoms. Due to impaired 
clearance function, patients with cystic fibrosis and patients after lung transplantation 
(LTx) may have prolonged exposure of the bronchial epithelium to gastric contents 
(Veale et al., 1993). This exposure to gastric contents may cause bronchial epithelial cells 
to initiate an inflammatory reaction that further impairs lung function (Perng et al., 2007). 
Pepsin and bile acids luminal gastroduodenal components, have been detected in 
bronchial material of LTx recipients (D'Ovidio et al., 2005b, Ward et al., 2005).  Damage 
to lung tissue could result due the presence of low pH along with pepsin and bile acids 
(Porembka et al., 1993, Knight et al., 2004)  
Ward and colleagues have published on pepsin as a marker of aspiration. Pepsin is a 
proteolytic enzyme which is found in the stomach. Pepsin has been used as a biomarker 
of extra-oesophageal reflux in cystic fibrosis and bronchiectasis. Another use has been as 
a possible indicator for gastric aspiration in lung transplant patients, with the potential 
association with pulmonary damage and lung disease (Ward et al., 2005). Pepsin can also 
be used as an extra-oesophageal reflux biomarker in glue ear as well its ole in aspiration 
with pulmonary damage and lung disease (Tasker et al., 2002a, Tasker et al., 2002b).  
Currently there is no consensus as to the best measurement technology for pepsin. Gastric 
juice contains 0.1-0.6 mg/ml of pepsin, so if it was aspirated neat then the alveolar fluid 
when sampled by broncho alveolar lavage might include about 1-6 µg/ml assuming (100 
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fold dilution from the wash out with (saline). Different values, from different studies on 
lung  
pepsin have been published (Metheny et al., 2002) for example, recorded levels of upto 
9.5µg/ml in suctioned tacheal secretions from patients recieving mechanical ventilation 
with no saline dilution. Implying that gastric juice has been diluted ≈ 60 times in the 
lungs, and the lungs do not contain neat gastric juice. Whereas (Blondeau et al., 2008a) 
recorded levels of 2µg/ml in BAL. This would fit with a 100x dilution of whole gastric 
juice, suggesting aspiration of whole gastric juice. The variability in the literature makes 
it difficult to compare results between groups (Haslam et al., 1999). In addition assay 
strategies vary and pepsin has been measured by both enzyme linked immunosorbent 
assay (ELISA) and by enzymatic activity (Badellino et al., 1996). 
Work in our lab to assess pepsin levels in BAL samples, used ELISA, in these studies 
transplant patients were compared with control volunteers, median BAL pepsin levels 
were, 8.3 vs 1.1ng/ml respectively (P=0.02). This demonstrated that pepsin can be present 
in transplanted lungs before significant airflow limitation develops (Stovold et al., 2007) . 
The study included 36 patients who went through a lung transplant procedure and were 
divided into three groups: medically stable, patients with acute vascular rejection, and 
BOS patients. 
Acute vascular rejection patients had the highest levels of pepsin as well as inflammation, 
suggesting a possible relationship relationship between non-alloimmunue injury 
(aspiration) and alloimmune elements of injury (acute rejection). Proton Pump Inhibitor 
(PPI) treatment did not affect pepsin levels. It is important to note that in this study the 
effect of time post transplant was not considered when measuring pepsin levels (Stovold 
et al., 2007). Consequently a longitudinal study is required.  
Finding pepsin in BAL samples in the afore mentioned patients indicates the presence of 
micro-aspiration and this is also true in patients on proton pump inhibitor therapy. This 
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therapy does not preclude reflux but at least it should decrease the acidity (Wise and 
Murray, 2007). Consequently pepsin is a good candidate as a biomarker of 
reflux/aspiration if a sensitive and reproducible assay is widley available.  
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1.3 Bile acids as a marker of reflux and aspiration 
 
 
The bile acids are modified steroids and therefore can be named as acidic sterols (Klyne, 
1959). The principal bile acids synthesized by the human liver (Bjorkhem et al., 1983, 
Russell and Setchell, 1992) have hydroxyl groups substituted at the carbon positions C-3, 
C-7, and C-12. Relatively high proportions of bile acids hydroxylated at the C-1, C-2, C-
4, and C-6 positions have indicated that alternative pathways for bile acid synthesis and 
metabolism become quantitatively important during early development (Lester et al., 
1983, Setchell et al., 1988). The two bile acids referred to as ‘primary’ bile acids and 
synthesized by the liver are cholic acid (3a,7a,12-atrihydroxy- 5b-cholanoic acid) and 
chenodeoxycholic acid (3a,7a-dihydroxy-5b-cholanoic acid). In vivo these bile acids are 
greater than 90% conjugated to the amino acids glycine and taurine (Sjovall, 1959). The 























Figure 2: The biosynthetic pathway for the primary bile acids pathway and the alternative or acidic pathway taken from (Heubi et al., 2007). 
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 In humans, the major solutes in bile consist of bile acids conjugated with glycine and 
taurine while unconjugated bile acids are almost non-detectable in normal bile (Bjorkhem 
et al., 1983). Conjugated bile acids have a less toxic character because they are less lipid 
soluble and remain more efficient promoters of intestinal absorption of dietary lipid when 
compared with unconjugated bile acids (Vessey et al., 1977). The relative amounts of 
taurine- and glycine-conjugated bile acids differs significantly among species (Johnson et 
al., 1991). Taurine conjugation dominates the newborn in humans; while in the adulthood, 
dependending on the dietary intake of amino acids, the ratio of glycine– to taurine–bile 
acid conjugates in bile is about 3.5:1 (Hardison and Grundy, 1983). 
It is now widely believed that refluxed bile acids play a significant role in the initiation 
and promotion of Barrett's oesophagus and cancer (Attwood et al., 1992, Stamp, 2002, 
Gillen et al., 1988). Barrett's metaplasia patients have higher levels of bile exposure and 
the proportions of secondary bile acids have been found at increased levels in their 
refluxate (Nehra et al., 1998). Furthermore, complicated cases of Barrett's patients with 
early adenocarcinoma have relatively higher exposure to bile acids compared to 
uncomplicated Barrett's patients (Stein et al., 1998). It has also been suggested that 
unconjugated bile acids play an important role in the progression of the neoplastic 
sequence in oesophageal cancers (Jankowski et al., 1993, Kauer et al., 1995). However, 
the relative roles that bile acids and stomach acid play are subject to further investigation 
and debate (Triadafilopoulos, 2001). Due to the fact that despite undergoing acid 
suppression therapy, certain patients continue their progress to adenocarcinoma, it has 
been suggested that factors other than acid could be equally important in Barrett's 
carcinogenesis.  
Bile acids are known to be capable of causing multiple injuries such as inducing DNA 
damage (Venturi et al., 1997) chromosome aberrations  (Jenkins et al., 2004), and causing 
gene expression abnormalities (Tselepis et al., 2003, Kaur et al., 2000). Hence bile acids 
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may be considered as potential causal factors for oesophageal carcinogens. Bile acid 
induced apoptosis (Lapre et al., 1992) coupled with the compensatory proliferation 
occuring in vivo has implicated bile as both an initiator and promoter of cancer 
development.  
Deoxycholic acid (DCA) derived from the bacterial degradation of the primary bile acid 
cholic acid (CA) in the colon, has been proposed as a factor in the aetiology of breast 
cancer (Hill et al., 1971, Lewis and Heaton, 1999). DCA concentrations found in human 
breast cyst fluid are (17-160 /µmol/L) (Raju et al., 1990, Javitt et al., 1994), the mean 
concentration for DCA in plasma was (0.43 µmol/l) (Costarelli and Sanders, 2001). 
Since the early 1960s, the effects of the monohydroxy bile acid lithocholic acid (LCA) 
has been studied as a hepatotoxic factor in the pathogenesis of cholestatic liver injury in 
rodents i.e., rat, hamster, and rabbit (Hofmann, 2004, Palmer and Ruban, 1966, Miyai et 
al., 1977, Hofmann, 1999b). This has led to increased understanding of the pathogenesis 
of LCA-induced cholestasis in rodents, the key concepts have included biochemical 
alterations of the bile canalicular membrane (Kakis and Yousef, 1978, Kakis et al., 1980) 
the development of crystalline plugs in bile canaliculi due to the poor solubility of LCA 
(Miyai et al., 1977, Bonvicini et al., 1978) and impaired trafficking or increased retrieval 
of canalicular export pumps to and from the canalicular membrane (Kubitz et al., 2004, 
Beuers et al., 2003). In addition, the role of hepatic metabolic phase I and II detoxifying 
enzymes and their regulatory nuclear receptors in the hepatic defense against toxic bile 
acids has been investigated extensively in gene knockout mice. (Staudinger et al., 2001, 
Xie et al., 2001, Sinal et al., 2000, Kitada et al., 2003, Schuetz et al., 2001, Saini et al., 
2004). However, the cholestatic phenotype and the pathogenesis of hepatobiliary injury of 
LCA-treated mice are not well understood. Hepatocytes, as well as bile duct epithelial 
cells (cholangiocytes) are affected by toxic bile acids (Lazaridis et al., 2004). Under 
physiological conditions, transportation of bile acids and biliary phospholipids into bile 
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takes place via the bile salt export pump (Bsep/Abcb11) and the canalicular phospholipid 
flippase (multidrug resistance gene 2 [Mdr2]/Abcb4) respectively, and subsequently it 
forms mixed micelles which protects cholangiocytes from bile acid toxicity (Trauner and 
Boyer, 2003). 
Several epithelial diseases such as bronchial asthma, atopic dermatitis, and inflammatory 
bowel diseases have in common eosinophils as important effectors cells (Kita H, 1998, 
Gleich et al., 1993, Gleich, 2000). Epithelial injury induced by activated eosinophils takes 
place through release of cytotoxic granule proteins, superoxide radicals, lipid mediators, 
and various cytokines (Gleich, 2000, Gleich et al., 1993, Kita H, 1998). Out of these, 
cytotoxicity of eosinophil granule proteins against various epithelial cells has been well 
established (Gleich et al., 1979, Frigas et al., 1991). However, there is increasing 
evidence for a role of eosinophils in the pathogenesis of immune-mediated diseases of 
bile duct epithelia (Neuberger, 1999, Yamazaki et al., 1996). Blood and tissue 
eosinophilia in the liver have been associated with primary biliary cirrhosis (PBC) 
(Yamazaki et al., 1996, Neuberger, 1999, Terasaki et al., 1993), primary sclerosing 
cholangitis (Neeman and Kadish, 1987, Noguchi et al., 1992), hepatic allograft rejection 
(de Groen et al., 1994), and chronic graft-versus host disease (Nonomura et al., 1996). 
Indeed, an observation regarding eosinophil degranulation in the vicinity of injured bile 
ducts in patients with PBC has been well-documented (Yamazaki et al., 2001, Terasaki et 
al., 1993). However, the mechanism(s) of eosinophil activation in these immune 
cholangiopathies, remains unknown. The most abundant biliary constituent, the bile acids 
are synthesized in the liver and secreted into the bile canaliculus, from where they are 
transported along the biliary and intestinal tracts (Nonomura et al., 1996). Sakisaka et al,  
have suggested that, luminal bile acids cross damaged epithelia and affect the functions of 
periductal immune cells after the structural integrity of biliary or intestinal epithelia has 
been impaired (Sakisaka et al., 1997). Interestingly, bile acids have heen shown to 
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possess diverse immunomodulatory actions toward lymphocytes (Yoshikawa et al., 
1992), monocytes (Calmus et al., 1992), macrophages (Ljubuncic et al., 1996), NK cells 
(Nishigaki et al., 1996), neutrophils, (Beuers et al., 1990) and mast cells (Yamazaki et al., 
2001). The relevance of this to the lung transplant situation is that many of these cell 
types are present in elevated levels (Gerhardt et al., 2003b).  Bile salts have been shown 
to upregulate the tissue destructive potential of these cells e.g. Taurochenodeoxycholic 
acid stimulates Eosinophil degranulation, IL-8 and superoxide production (Yamazaki et 
al., 2001).  Consequently the reflux and aspiration of bile salts will enhance the ability of 

















1.4 Bile acids in cystic fibrosis patients. 
 
The recent history of gastro-oesophageal reflux (GOR) in cystic fibrosis (CF) disease can 
be traced to 1975 when it was first reported in patients with CF. Today, its prevalence in 
CF is estimated to be between 35 and 81 %.(Brodzicki et al., 2002, Ledson et al., 1998, 
Scott et al., 1985, Vic et al., 1995). Increased GOR in CF could be a secondary 
phenomenon during cough and/or physiotherapy resulting from an increased abdominal–
thoracic pressure gradient (Ledson et al., 1998). In CF patients, the characteristics of 
GOR might be affected by the modifications in the volume of gastric contents, acidity and 
concentration of bilio-pancreatic components. Combined impedance–pH monitoring is a 
technique that allows detection of all types of gastro-oesophageal reflux events i.e. both 
acid weakly acidic and alkaline (Sifrim et al., 2004). However, the incidence of weak 
acidic reflux in patients with CF is currently unknown (Blondeau et al., 2007, Sifrim et 
al., 2005, Tutuian et al., 2006). The most important concern about GOR in CF is the 
possible deterioration of lung function resulting from reflux induced lung aspiration of 
gastric contents. This assumption has been empirically supported by the observation that 
CF patients with increased acid GOR had poorer lung function than those without 
abnormal GOR (Navarro et al., 2001). However, prevalence of GOR and poor lung 
function together cannot be taken as the proof of causal relationship between them, some 
studies data have shown the abnormal presence of gastric contents in bronchial secretions 
of CF patients (Blondeau et al., 2008a). Some recent studies focussing on patients after 
lung transplant (LTx), including transplanted CF patients, have reported the presence of 
markers of gastric contents in bronchoalveolar lavage (BAL) obtained during 
bronchoscopy (Blondeau et al., 2008b). However, it remains to be determined whether or 
not CF patients had higher levels of lung aspiration than other LTx patients. 
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The most common genetic disorder of the Caucasian population is cystic fibrosis (CF) 
(Steinberg and Brown, 1960). The disease is characterized by the involvement of different 
exocrine glands (Park and Grand, 1981), making it an extremely heterogeneous disease. 
The prognosis of cystic fibrosis depends largely upon the extent of respiratory 
involvement and the presence of serious complications like biliary cirrhosis. Around 
thirty years ago there was a proliferation of research aimed at investigating bile acid 
metabolism in patients with cystic fibrosis (Goodchild et al., 1975, Roy et al., 1977, 
Watkins et al., 1977, Harries et al., 1979). However, a clear understanding of the 
mechanisms has been complicated by the fact that both intestinal absorption and hepatic 
extraction of bile acids are potentially impaired. CF patients with pancreatic insufficiency 
suffer from bile acid malabsorption (Weber et al., 1973, Weber et al., 1976, Smalley et 
al., 1978). This may suggest that overall there is a greater potential for reflux of bile acids 
in CF. The pathophysiological significance is uncertain and the consequences are rather 
vaguely understood however. Similarly, serum bile acid concentrations in patients with 
CF have been studied on a limited scale (Davidson et al., 1980, Colombo et al., 1983, 
Strandvik and Samuelson, 1985, Colombo et al., 1984, Setchell et al., 1985).  
1.4.1 Bile acids in sputum 
 





percentile 2.4-6.1) than chronic cough patients, median 0.72µmol/l (0.2 – 1.2) and more 
than patients with Gastro-oesophageal reflux disease median 1.23mmol/l, (1.2–2.3) 
(p 0.05). A study of 38 patients was performed and only 16 who had DF508 
homozygote genotype proved to have bile acids. On the other hand, bile acids were found 
in sputum of 4/10 chronic unexplained cough patients. No bile acids were found in 
healthy controls (Blondeau et al., 2008b). 
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1.4.2 Bile acids in bronchoalveolar lavage 
 









 percentile (0.3–1.3)]. 60% of CF transplanted patients (6/10) and 
10/24 of non CF-transplanted patients (41%) had bile acids, while non transplanted 
patients (43%) had bile acids. No typical GOR symptoms were found in (59%) CF 
patients who had bile acids in BAL or saliva (Blondeau et al., 2008b) 
1.4.3 Gastro-oesophageal reflux, gastric aspiration and respiratory status 
 
CF patients who do not have bile acids in sputum had higher levels of lung function 71% 
(61–79%) than CF patients who have bile acids in sputum 61% (38–82%) (FEV1% 
predicted). Transplanted CF patients, with bile acids had a trend for a lower lung 
function.  
Bronchiolitis obliterans syndrome (BOS) developed in 1/3 patients who had bile acids in 
BALF. No BOS was developed in patients who did not have bile acids in the BALF 









1.5 Bile acids in lung transplantation    
 
Bile acid aspiration can cause serious pulmonary damage (Henderson et al., 1975, 
D'Ovidio et al., 2005a). As confirmed by in vitro studies on Type II pneumocytes, bile 
aspiration injures the cell membrane and modifies cationic penetrability (Oelberg et al., 
1990, D'Ovidio et al., 2005a, D'Ovidio and Keshavjee, 2006). Bile acids have different 
effects depending on the site they are in. If they are in the stomach, the mucosa wall could 
be injured but it is reasonably well protected by mucus. In addition solubility becomes a 
factor at low stomach pH levels. In the lungs, the mucosal layer might be disturbed as a 
result of the physical effect they can have on lipids in surfactant. Type II pneumocytes, 
which are responsible for lung homeostasis, phospholipid production and surfactant 
proteins could be damaged by bile acids. Bile acids may also cause downregulation of 
innate immunity receptors on monocytes and macrophages (D'Ovidio et al., 2006b). By 
reducing phagocytosis and LPS mediated cytokine production, bile salts can lead to the 
reduction of macrophage function, as shown in rabbits. Bile acids can also downregulate 
interferon-mediated signal transducers (D'Ovidio et al., 2006b). 
Regional innate immunity can be disturbed by bile aspiration, and this can consequently 
have an influence on the balance of innate and adaptive immunity and promote local 
infection, causing a more hostile adaptive immunity (D'Ovidio et al., 2006b). Activated 
macrophages and injured epithelial cells can accelerate allo-immunity. (Davis et al., 
2003a). This shows potential cross-talk between adaptive and innate immunity (D'Ovidio 
et al., 2006b).    
Raised neutrophils and IL-8 levels, the presence of bacteria, fungi, lower levels of 
pulmonary surfactant and higher inflammatory grades on transbronchial biopsy, have all 
been linked to the presence of bile acids (D'Ovidio et al., 2006b). Cytokine production is 
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controlled by opsonins and lower levels of surfactant surface proteins A and D are 
associated with bile salt aspiration. The cytotoxic influences of bile acids are supported 
by augmented lipid sphingomyelin, a phospholipid which is related to tissue damage. This 
causes a modification in the mucosal defences (D'Ovidio et al., 2006b). An important 
problem with a lot of the studies on lung damage and bile acids are that the effects in vitro 
using very high levels of bile acids are being extrapolated to the lung where much lower 
levels may well be present in vivo. 
BOS grades, trans bronchial biopsies, microbiology examinations, the variance of cell 
counts, cytokine concentrations, and bronchoalveolar lavage bile acids were all estimated 
in a study of 120 patients who underwent lung transplant (D'Ovidio et al., 2005a).    
It was found that the average amount of bile acids in BOS positive patients was higher 
than BOS negative patients. The level was 1.6µmol/L (median) in BOS positive patients 
compared to 0.3µmol/L (median) in negative patients (p=0.002). Those who had late BOS 
(after one year) had lower levels of bile acids than early BOS patients (within one year). 
The level was 0.8µmol/L (median) compared to 2.6µmol/L (median) respectively 
(p=0.02) (D'Ovidio et al., 2005a). 
Blondeau et al supported the link between bile salts and BOS (Blondeau et al., 2008a). 
Patients with negative inflammation scores on biopsy had lower average level of bile salts 
than those with positive biopsy (median 0.2µmol/l and median 1.1µmol/l respectively). 
The median level of bile salts in patients with negative microbiology samples was lower 
than patients with positive microbiology samples, median 0.3µmol/l and median 
0.7µmol/l respectively. This supports a link between the development of infection and 
higher amounts of bile acid (D'Ovidio et al., 2005a). 
 The levels of neutrophils appear to depend on the levels of bile acids present. Patients 
with low levels of bile acids have a level of 2-5% neutrophils (BALF differential cell 
count percentage), compared to patients with no detectable levels of bile acid who show 
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2% or lower levels of neutrophils (D'Ovidio et al., 2005a). This could be important as 
neutrophil levels are associated with acute rejection and BOS (Riise et al., 1998, Zheng et 
al., 2005). Since the bronchoalveolar pH favours activity of duodenal pancreatic agents, 
the duodenal reflux could be more damaging than chronic acid aspiration. BALF bile 
acids and abnormal pH in lung transplant patients are linked (D'Ovidio et al., 2005a). A 
limitation of most of the current literature regarding bile acid aspiration is that insensitive 
spectrophotometric techniques have been used to quantify levels. In our lab the limit of 
quantification of such methods is ≈ 5µmol/L. It is therefore difficult to interpret many 











1.6 Neutrophilic inflammation and cytokines  
 
Many inflammatory lung diseases involve neutrophil inflammation, (Goya et al., 2003) as 
well as the CXC chemokine, interleukin (IL-8). Asthma (Vu et al., 1998), adult 
respiratory distress syndrome (McQuibban et al., 2002), chronic obstructive pulmonary 
disease (COPD) and cystic fibrosis (CF) as well as BOS are good examples of these 
diseases. Lymphocyte chemoattractant factor, granulocyte-macrophage colony-
stimulating factor (GMCSF), and members of the chemokine superfamily constitute 
chemotactic cytokines. Primarily their function relates to the migration of inflammatory 
cells to sites of injury and disruption. Depending upon the presence or absence of an 
amino acid between the first two of four conserved cytokines, members of the chemokine 
superfamily are further divided into A and B subgroups. Several studies have 
demonstrated that one of the most potent chemoattractants and activators of neutrophils, 
on a molar basis, is the chemokine interleukin 8 (IL-8), IL-8 is synthesized and released 
in great quantities from airway epithelial cells (Khair et al., 1995, Devalia et al., 1993, 
Baggiolini et al., 1992). IL-8 has been of particular interest in studies investigating the 
pathogenesis of chronic bronchitis and COPD due to its important effects on neutrophil 
cell biology (Keatings et al., 1996). IL-8 has also been shown to be a chemoattractant for 
eosinophils and therefore may also play a role in the pathophysiology of allergic airway 
diseases (Wang et al., 1996, Sousa et al., 1994). In humans, IL-8/CXC ligand 8 (CXCL8), 
the prototypical neutrophil specific. 
CXC chemokine is known as key mediator of acute inflammation (Baggiolini and Clark-
Lewis, 1992). IL-8/CXCL8 concentrations are associated with inflammatory conditions 
such as necrotizing enterocolitis in the developing intestine, where they are elevated in 
serum and tissue (Edelson et al., 1999, Viscardi et al., 1997). Biologically significant IL-
8/CXCL8 concentrations in swallowed amniotic fluid (Denison et al., 1998, Kemp et al., 
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2002), and breast milk (Srivastava et al., 1996, Michie et al., 1998, Maheshwari et al., 
2002, Maheshwari et al., 2003), prove that the human fetal /neonatal gastrointestinal 
lumens are normally exposed to these chemicals. Tested by enzyme immunoassay, an in 
vitro model of neonatal gastric and proximal intestinal conditions has shown that IL-
8/CXCL8 remains undigested (Maheshwari et al., 2002). In intestinal epithelial cell (IEC) 
lines, recombinant human IL-8/CXCL8 promotes cellular migration, proliferation, and 
differentiation as well as protecting these cells from chemical injury (Maheshwari et al., 
2002). The intact survival of IL-8/CXCL8 through gastric digestion needs confirmation in 
assays for structural and functional integrity and it would be desirable to assess the 
physiologic relevance of the above listed effects. 
Interleukin 6 (IL-6) is another multifunctional cytokine synthesized and released by 
airway epithelial cells. This cytokine has pleotropic proinflammatory effects on a number 
of target cells. It is also involved in the activation of B lymphocytes and monocytes. It is 
known to induce acute-phase protein synthesis (Devalia et al., 1993, Abdelaziz et al., 
1997, Borish and Rosenwasser, 1996, Levine, 1995).  
IL-6 has been shown to influence the expression of cell adhesion molecules (Hutchins 
and Steel, 1994). 
Key roles of IL-6, IL-8 and GMCSF in the regulation of airway inflammation and 
pathophysiology of COPD have been documented in many studies (Ruiz et al., 2002). In 
vitro studies have shown that these pro-inflammatory cytokines inhibit apoptosis of 
granulocytes (Lee et al., 1993, Leuenroth et al., 1998, Brach et al., 1992, Castro-Alcaraz 
et al., 2002). In addition IL-8 has been of particular interest in studies investigating the 
pathogenesis of chronic bronchitis and COPD, due to its important effects on neutrophil 
cell biology (Keatings et al., 1996). 
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1.7 Alloimmune and non alloimmune injury  
 
There have been some improvements in 1-year survival rates post lung transplant, 
however, compared with transplantation of other solid organs, the long-term outcome 
after lung transplantation remains poor. At 5 years, the survival rates of lung transplant 
recipients are only 49% which further decline to 25% at 10 years (Trulock et al., 2006). 
The main cause for late death after lung transplantation is a manifestation of chronic 
allograft rejection called bronchiolitis obliterans syndrome (Estenne and Hertz, 2002, 
Okazaki et al., 2007). The pathologic changes of bronchiolitis obliterans syndrome are 
referred to as bronchiolitis obliterans.  
The human airway epithelium plays a major role in responding to injury, infection, or 
toxins by producing various cytokines and mediators which modulate airway 
inflammation. Certain exogenous or endogenous stimuli, such as granulocyte-macrophage 
colony-stimulating factor (GMCSF) regulate and activate normal T-cell expression and 
secretion (Wu et al., 2009). Tumour necrosis factor-α ; prostaglandin E2; or transforming 
growth factor-β1 can directly drive epithelial cells to increase the generation of IL-8 
(Khalifah et al., 2004, D'Ovidio et al., 2005b, Groetzner et al., 2006, Novick et al., 1998, 
Brugiere et al., 2003, Hertz et al., 1993). Resulting damage to the airway epithelium may 
induce a fibrotic response (Holgate, 2000). The loss of airway epithelial cells and partial 
or complete occlusion of the lumina of terminal and respiratory bronchioles by 
inflammatory and fibrous tissue are considered as the histologic hallmarks of the 
bronchiolitis obliterans syndrome. Airway epithelial cells are thought to represent an 
important cellular target during lung allograft rejection; although the precise mechanisms 
leading to the development of bronchiolitis obliterans are poorly understood.  
It has been hypothesized that excessive fibroproliferation is caused by injury and 
apoptosis of airway epithelial cells with subsequent aberrant tissue repair (Gourishankar 
24 
 
and Halloran, 2002). Development of bronchiolitis obliterans after lung transplantation 
has been attributed to risk factors which have been subdivided into alloimmune-
dependent and alloimmune-independent factors. It has been suggested that the frequency 
and severity of acute rejection episodes and the subsequent development of chronic 
rejection could also be inter-related (Hachem et al., 2005). Ischemia / reperfusion injury, 
bacterial and viral respiratory infections are potential injuries (Daud et al., 2007, Khalifah 
et al., 2004, D'Ovidio et al., 2005b). Food particles, bile acids, pepsin, trypsin, other 
enzymes, and bacteria or their products, are all part of the non-acidic component of 
gastric juice (Mertens et al., 2010). Gastric juice therefore constitutes a potential 
alloimmune-independent risk factor if aspiration occurs shown in Figure 3 (Daud et al., 
2007, Khalifah et al., 2004, D'Ovidio et al., 2005b). All gastric juice factors are potential 
pro- inflammatory stimuli, which directly damage the airway epithelium or indirectly 
influence the alloimmune response by altering the milieu in the lung allograft to increase 
antigenicity. Bronchiolitis obliterans is generally not reversible, therefore, once 
established, therapeutic options remain limited. In the majority of these patients, the 
augmentation of immunosuppression has failed to prevent the progression of fibrotic 
airway obliteration leaving retransplantation as the only option (Groetzner et al., 2006, 
Novick et al., 1998, Brugiere et al., 2003). Indicating that alloimmune driven process are 





















































Figure 3: Potential model of epithelial cells and alloimmune non alloimmune injury infection 












The interface between the internal milieu and the external environment is established by 
the epithelium. This interface will form the first point of contact for inhaled substances 
such as respiratory viruses, airborne allergens and environmental or aspirated pollutants. 
It will also become a target of inhaled drugs (Gizycki et al., 1997, Folkerts and Nijkamp, 
1998). The main role of the respiratory epithelium as previously recorded was of a 
physical barrier. However, the importance of the airway epithelial cells (AEC) in 
controlling various inflammatory responses observed in most respiratory diseases and 
especially in asthma is increasingly recognised. The complex nature of AEC interactions 
with a range of cells and processes can be well demonstrated in the airway response to 
injury (Busse et al., 1999). Additional functions of AEC has been identified because of 
the inflammatory cytokines and growth factors that AEC produce. These functions are: 
1- A contribution to repair processes. 
2- Remodelling, this can be marked in asthma and other diseases involving airway 
fibrosis. 
3- Regulation of various immune responses (Holgate et al., 2000) . 
Moreover, nitrogen dioxide (Vagaggini et al., 1996) and some particulate matters 
(Nordenhall et al., 2001) are environmental pollutants that are known to make asthma 
patients more sensitive to the proinflammatory effects. It was found that there is a 
difference between the cytokines released from AEC from asthma patients and healthy 
people. Cultured bronchial epithelial cells (HBEC) (Devalia et al., 1999) secrete various 
proinflammatory mediators which were examined by Devalia and co-workers both 
constitutively and following challenge with diesel exhaust particles (DEP). These studies 
showed that large quantities of interleukin (IL-8) (Lordan et al., 2002) are liberated from 
HBEC of asthma patients following DEP challenge. It is of interest that recent studies 
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have shown that there is an association between lung allograft failure, death and 





1.8 Overall aims  
 
Primary bronchial epithelial cells from explanted CF lungs, lung transplant patients’ and a 
goblet cell line will be cultured to assess the effect of bile salt and gastric aspirate 
challenge. The effect of cholic acid, chenodeoxycholic acid, deoxycholic acid, lithocholic 
acid, taurodeoxycholic acid, taurocholic acid, porcine pepsin, gastric juice samples and a 
bile acid mixture will be measured by assessment of inflammatory cytokine production. 
Markers will include IL-8, IL-6 and GMCSF which are important in neutrophil 
inflammation, lung transplant rejection and epithelial homeostasis. Interleukin-8 in 
common with IL-6 is a significant driver of mucus hyper-secretion as well as neutrophilic 
inflammation. Cell viability will also be assayed. 
 
1.8.1 Specific aims 
 
 To quantify injury in cultured primary epithelia following incubation with gastric 
juice, the acid protease pepsin, and bile salts. 
 To investigate the effect of incubation with gastric juice, the acid protease pepsin, 








Materials and Methods 
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2.1 Collection of samples 
 
2.1.1 Collection of lung recipient samples 
 
In order to facilitate the study of epithelial cell responses in vivo during the pathogenesis 
of BOS and end stage lung disease, the current study used methods for primary bronchial 
epithelial cell culture from lung allografts. Ethical approval for the study was granted 
from the Newcastle and North Tyneside 2 (reference number 2001/179), informed 





In brief the patients who were studied all underwent the following: 
1- Lung function tests. 
2- Standard assessment for BOS status (Estenne and Hertz, 2002). 
3- Collection of bronchial brushings from lung transplant recipients during 
bronchoscopy (Forrest et al., 2005). 
4- Bronchoalveolar lavage (BAL) of the right middle lobe or lingula, assessed routinely 
for microbiology (Yousem et al., 1996). 
5- Transbronchial biopsies in order to diagnose acute vascular rejection according to 




 Gender Date of birth Reason for 
transplant 
Date LTx Age One lung or two 
transplanted 
Date BAL BOS 
stage 
Biopsy score Microbiology 
TW 1015 M 08.03.1957 IPF 05.04.2006 49 SL 03.10.2008 1 Ax B0 Negative 
           
TW 1029 F 18.03.1961 LAM 06.11.2007 46 SSL 05.11.2008 NK A0 B0 C0 Negative 
           
TW 1080 F 06.06.1961 Emphysema 13.01.2008 47 SL 11.03.2009 1 A0 B1R(B2) Negative 
           
TW 1090 M 13.05.1948 Emphysema 02.09.1999 51 SL 01.05.2009 1 Ax BIR C2 Negative 
         (Ax B1 Ca)  
TW 1131 M 12.05.1978 CF 08.05.2008 30 SSL 28.08.2009 1 A0 Bx Cx Negative 
           
TW 1140 M 27.04.1956 COPD 31.03.2009 53 SSL 28.09.2009 1 Ax Bx Cx Negative 
           
TW 1142 M 02.04.1961 COPD Bronch 12.07.2009 48 SSL 30.09.2009 0 Ax Bx C0 Pseudomonas 
aeruginosa 
           
TW 1162 M 08.11.1962 Fib Lung Dis 02.06.2009 47 SL 02.12.2009 0 Ax Bx C0 Candida Albicans 
           
  
Table 1: The clinical details of LTx patients  
Key: TW numbers=individual patient number (anonymised), M=Male, F=Female, Reason for transplant indicate the lung disease that resulted in the 
need for lung transplamt. IPF=Idiopathic Pulmonary Fibrosis, LAM=Lymphangioleiomyomatosis, CF=Cystic Fibrosis, COPD=Chronic Obstructive 
Pulmonary Disease, Bronch=Bronchiectasis, Fib Lung Dis=Fibrotic lung disease. Biopsy score=Pathologist score for rejection derived from 




2.1.2 Collection of cystic fibrosis samples 
Ethics and Consent 
Approval was obtained for this study from the Newcastle and North Tyneside 2 Research 
Ethics Committee reference number 07/Q0906/47. The study was also approved by the 
Research and Development Department of the Newcastle upon Tyne Hospitals 
Foundation NHS Trust. 
Dr Malcolm Brodlie obtained informed consent from all participants at the time 
ofacceptance on to the active lung transplantation list at the Freeman Hospital. 
2.1.3 Collection of Gastric juice samples  
Ethics and Consent  
Ethical approval was obtained from the County Durham & Tyne Valley 2 Reserch Ethics 
Committe (reference number 07/H0908/70). Research & Development approval was 
granted by the Newcastle Upon Tyne Hospital Trust Research & Development 
Department.  
 
After informed consent gastric juice was collected at routine endoscopy undertaken at a 
local gastroenterology clinic with Gastric juice obtained from both lung transplant 
recipients and non transplant related patients by Dr Andrew Robertson.  The contents of 
these samples were then tested to determine total bile acids levels and pH by Miss Shruti 
Parikh. Pepsin activity was measured by Dr Bernard Verdon. The pathogen results were 
provided by the Freeman Road Hospital Microbiology lab (courtesy of Prof John Perry 
and Ms Audrey Nicholson).Data is presented in Table 9. Fractions of the samples were 
filtered to remove any remaining pathogens. This was done by pushing samples through 
0.22μm sterile filters (Millipore) by sterile syringes (Millex). Small molecular weight 
molecules were removed by filtration and dialysis. To do this aliquouts of Gastric Juice 
were left overnight in deionised water, in 19mm dialysis membrane (Scientific 
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Laboratory Supplies ltd, UK), with this process removing molecules with a molecular 




2.2 Cell culture methods  
 
2.2.1 Bronchial epithelial cell isolation and culture from brushings 
 
Bronchial epithelial cells were cultured from airway brushings taken from lung transplant 
patients at the time of clinically indicated bronchoscopies. This method was previously 
published by Forrest et al. and is outlined as follows (Forrest et al., 2005). Patients were 
pre-treated with intravenous midazolam and topical 4% lignocaine before undergoing 
bronchoscopy (Using an Olympus FB 45.5 bronchoscope; Olympus, Tokyo, Japan) (Mills 
et al., 1999). Lignocaine was applied to the vocal cords and tracheal lumen in 1ml 
aliquots to a maximum dose of 7mg per kg of body weight. Protected specimen single-
sheathed nylon cytology brushes were used to collect bronchial brushings from 
subsegmental bronchi. These bushings were immediately placed into Roswell Park 
Memorial Institute Media (RPMI). 
The suspended samples were centrifuged for seven minutes at 1100 rpm, and the cell 
pellet was than resuspended in 2ml of Clonetics bronchial epithelial cell basal medium 
(Clonetics BEBM, (Lonza), San Diego, CA, USA) together with bronchial epithelial cell 
growth medium (BEGM) single quots (Clonetics,) (Table 5), 50U/ml penicillin, 50mg/ml 
streptomycin (Sigma, UK), 50mg/ml gentamycin, and 50µg/ml amphotericin B (Lonza, 
USA). These were the final antimicrobial concentrations in the culture medium 
throughout the process. 
Cell suspensions were put in to a T25cm
 
flask pre-coated with collagen (Vitrogen 100, 
cohesion, Palo Alto, CA, USA) and placed in a CO2 incubator (37C
°
/5% CO2). After the 
first 48 hours a further 3ml of supplemented medium was added with subsequent 
exchange (3 ml) every 48 hours, until primary bronchial epithelial cell cultures (PBECs) 
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reached 80%-95% confluence. Once confluent, PBECs were passaged using 3ml of 
trypsin, which was neutralised using an equal volume of RPMI supplemented with 10% 
of foetal calf serum (FCS). PBECs were then put in 10ml of culture medium and 
transfered to Vitrogen (Cohesion) coated T75cm
2
 flasks, 24 well plates or to eight 
chamber slides, (Lab-Tek, Nunc, Naperville, IL, USA; Chamber-1). Which were cultured 
to 80-95% confluence.  
 2.2.2 Cystic fibrosis epithelial cell culture  
 
Initial dissection and preparation of cells through to passage 1 into T25 flasks were 
carried out by Dr. M Brodlie and Dr. Chris Ward.   
Cystic fibrosis cells were cultured from resected lungs, from patients with end stage 
disease, at the time of transplantation (Brodlie et al., 2010).  
The lungs removed at the time of transplantation were examined by a consultant 
pathologist, Dr. Fiona Black, both macroscopically and histologically. This examination 
aimed at confirming the pre-identified disease and diagnosing other unidentified diseases, 
for example a malignancy before the transplantation. 
After collecting clinical samples for microbiology and virology examinations, the 
explanted lungs were stored at 4
o
C. The tissue was then processed, usually less than 60 
minutes after the explantation. The later culturing work was done in a class II laminar 
flow hood using a meticulous aseptic technique. Around 0.5 cm to 2 cm pieces of the 
main bronchus were then resected from the connected lymphoid, alveolar and vascular 
tissues. Four pieces of bronchus were taken out of each lung, rinsed twice at 4
o
C in 25 ml 
of sterile phosphate buffered saline (Sigma-Aldrich) (Figure 4 and Figure 4a). The rinsed 
tissue was then immersed in 20ml of washing solution A at 4
o
C see (Table 2). The 
solution was agitated for 30 minutes, and then the pieces of bronchus were rinsed twice at 
4
o
C in 25ml of Dulbecco’s Modified Eagle’s Medium (DMEM) to be later immersed in 
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20 ml of the washing solution B at 4
o
C (Table 3). The tissue was then agitated for 48 to 
72 hours (4
o
C) at 50 HZ on a rocker-shaker set. 
 
Component Concentration Supplier 
DMEM Neat Invitrogen 
Dnase 10µg/ml Sigma -Aldrich 
Dithiothreitol 500µg/ml Sigma- Aldrich 
Designated    Antimicrobials                            See Table -3 
 
Table 4: Constituents of Washing Solution A 
 
Expert advice from Professor John Perry, Clinical Scientist, Microbiology Department, of 
the Freeman Hospital helped in the choice of the antimicrobial combination used in 
Washing Solution B (Table 3).  The organisms (and sensitivity results) recently taken 
from the sputum of a specific patient were taken into consideration where possible. All 
the used antimicrobics and their concentration are shown in (Table 4) . The data 
published by Randell et. al (2001) concerning the relative cytotoxicity of different agents 
in primary bronchial epithelial cell cultures and a discussion with Professor Perry 




Component Concentration Supplier 
DMEM Neat Invitrogen 
Dnase 1µg/ml Sigma -Aldrich 
Protease  1% Sigma- Aldrich 
Designated   Antimicrobials                           See Table -4 
 





Figure 4a:  Epithelial cell removal after protease dissociation. The concave, luminal airway 










Figure 4b: Rinsing and collecting the scraped cells (Fulcher et al., 2005) 
 
The bronchial cells were harvested after being put for 48 to 72 hours in washing solution 
B (Table 3). 5ml of Roswell Park Memorial Institute-1640 (RPMI) (Invitrogen) 
containing 10% Fetal Calf Serum (FCS) (Invitrogen) was added to the solution to 
neutralise any remaining protease. Subsequently, the pieces of bronchus were transferred 
to a sterile petri dish. The luminal side of the bronchi was lightly scraped using a scalpel 
blade to remove the epithelial cells (Figure 4a). The scraped cells were later immersed in 
10ml of RPMI containing 10% FCS and centrifuged at 1000 rpm for 5 minutes. After 
discarding the supernatant, the cells were resuspended in 5ml of Bronchial Epithelial 
Basal Medium (BEBM) (Clonetics) warmed to 37° C and supplemented with the single 
quots described in (Table 5), 1% streptomycin , 1% penicillin and designated antibiotics 
as shown in(Table 4) (figure 4b). The resulting cell suspension was later seeded into 
25cm
2
 tissue culture flasks precoated with collagen (PureCol, Advanced BioMatrix, 




Antimicrobial Working Concentration in BEGM 
Ceftazidime 128 µg/ml 
Tobramycin  16 µg/ml 
Vancomycin  10 µg/ml 
Colistin  5 µg/ml 
Meropenem 100 µg/ml 
Co-Trimoxazole   12 µg/ml 
Ticarillin and Clavuantae 16 µg/ml 
Amphotericin B 4 µg/ml 
Voriconazole  10 µg/ml 
 
Table 6: Antimicrobial Working Concentration in Media (Fulcher et al., 2005) 
 
 
Component  Volume Added to 500 ml of BEBM 
Bovine Pituitary Extract 2 ml 
Insulin  500 µl 
Hydrocortisone   500 µl 
Retinoic Acid 500 µl 
Transferrin  500 µl 
Epinephrine    500 µl 
Human Epidermal Growth Factor 500 µl 
Tri- Iodothyronine  500 µl 
Gentamicin/ Amphotericin  500 µl 
 
Table 7: Bronchial epithelial cell growth medium (BEGM) Single Quots 
 
A careful observation of the PBEC cultures was maintained to make sure that the growth 
of the cells was satisfactory and to note any signs of infection. If signs were detected the 
flask was instantly removed from the incubator and its contents sent for routine bacterial 
and fungal culture to determine the infecting organism and the relevant antimicrobial 
sensitivities. It was presupposed that early infection episodes were due to the presence of 
organisms, resistant to the antimicrobial cocktail, emanating from the patient rather than 
introduced during the culturing process. The BEBM was changed every 48 hours. The 
designated antibiotics were normally removed from the BEBM after approximately 96 
hours of successful cell culturing free of overt infection. 
After flasks were around 80% confluent, the PBECs were passaged using 
Trypsin/ethylene diamine tetraacetic acid (EDTA) [Sigma] by applying the following 
method. First, the culture medium was isolated from the flask and replaced with 2ml of 
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trypsin/EDTA. Second, the adherents PBECs were removed by a gentle shaking action. 
The level of trypsinisation was determined by light microscopy. After it was ascertained 
that a sufficient number of cells had been lifted from the flask, the trypsin was neutralised 
by the addition of an identical volume of RPMI containing 10% FCS. The resulting 
suspension was then removed and centrifuged at 1100 rpm for 7 minutes at 20°C. The 
cell pellet was either resuspended in BEGM and seeded into flasks (Corning) or 24-well 
plates (Corning) for further submerged culture, or cryopreserved. The supernatant was 
discarded.  
 
2.2.3 Goblet cell line (HT 29MTX) culture 
The HT29-MTX cell line although of colonic origin shows rheologic changes 
characteristic of respiratory goblet cells in that is secretes MUC5AC a mucin secreted by 
a respiratory goblet cells and not MUC2 the mucus secreted by colonic goblet cells.  The 
human goblet cell line HT29-MTX, donated by Dr Thecla Lesuffler (INSERM U178, 
France), was grown at 37°C and 10% CO2 in a T75 flask in 12ml of Dulbeco’s modified 
eagles medium (Sigma, UK) supplemented with 10% FCS (Sigma, UK), 50U/ml 
penicillin, 50mg/ml streptomycin (Sigma, UK), 50mg/ml gentamycin, and 50µg/ml 
amphotericin B (both Lonza, USA). Media was changed every 48 hours until 75 to 85% 
confluence was reached. Cells were then passaged to a T75 flask, using the same method 
used for PBECs. Upon reaching confluence the cells were passaged to 24 well plates for 
experimental interventions. The wells contained 4-5x10
5





2.2.4 Epithelial Cell passage 
2.2.4.1 Epithelial Cell passage (common to CF samples and lung Tx brushing) 
 
When the cells grew to near confluence in the cell culture flask they required passage, for 
further growth or to allow experimentation. To do this the cell culture flask had 2.5 ml of 
trypsin EDTA added and was then incubated at 37 ºC for 3 to 5 minutes, 5ml of RPMI 
media was then used to resuspend the cells, and to stop the function of trypsin. The cells 
were pelleted by centrifugation for seven minutes at 1100 rpm and 20 ºC. Finally 12 ml of 
complete epithelial media was added and mixed gently. 24 well plates were then seeded 




2.2.5. Primary bronchial epithelial Cell (PBECs) and goblet cell (HT29 MTX) 
stimulation.  
 
When PBECs were 80-95% confluent 24 well plates were rested for 24 hours by the 
addition of serum free medium (BEBM, 50mg/ml gentamycin, and 50µg/ml amphotericin 
B (Lonza, USA), 50U/ml penicillin, 50mg/ml streptomycin (Sigma, UK)). Goblet cells 
were rested for 24 hours in serum free medium (DMEM, 50U/ml penicillin, 50mg/ml 
streptomycin (Sigma, UK), 50mg/ml gentamycin, and 50µg/ml amphotericin B (Lonza, 
USA)). Cells were stimulated with bile salts, pepsin or whole, filtrated and dialysed 
human gastric juice made up in resting medium. The initial solubilisation of bile salts 
cholic acid, chenodeoxycholic acid, deoxycholic acid, lithocholic acid, taurodeoxycholic 
acid, and taurocholic acid bile salts required methanol. All bile salts were solubilised in 
methanol then diluted with resting media to give required concentrations.  
Different concentrations of the bile salts, (0.25, 0.50, 75, 1, 5, 10, 25, 50, 100 and 
200µmol/L) as well as different incubation times 24, 48 hours were used. PBECs were 
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stimulated with porcine pepsin at concentrations of 25μg/ml, 50μg/ml and 100μg/ml for 
different incubation times 24, 48 hours.  
Samples of medium were collected at 24 and 48 hour intervals; control samples were also 
collected at these times. Controls consisted of cells incubated with resting media and 
methanol. The data presented in the thesis are all 48 hour results because the stimulations 
at 48 hours were more effective compared to 24 hour results. 
PBECs were stimulated for 24 hours, with 8 different gastric juice samples, gastric juice 
samples were diluted 1/1000, 1/2000 and 1/3000 in 500μl of the resting media. The eight 
human gastric juice samples were also filtered, dialysed as well as diluted by the same 
method. Gastric juice with pH between7-8 and diluted 1/1000 have previously been 
shown to stimulate large IL-8 levels from PBECs, (Mertens et al., 2010), I therefore 
standardised the pH of my gastric juice samples (pH 7.4), using 1/1000 dilution. 
 
PBECs were also stimulated with a bile acid mixture; the composition of this was based 
on concentrations of bile salts present in human bile (50% taurocholic acid, 15% 
taurodeoxycholic acid, 30% chenodeoxycholic acid and 5% lithocholic acid) (Allan et al., 
1976) (10µmol/l) for 48 hours. The conjugated bile acids were originally going to be used 
in the experiments, however the free acids were used as the conjugated forms were 




2.3 Cryopreservation of epithelial and goblet cells 
 
2.5 ml or 5 ml of trypsin (depending on the size of the flask) were added to the cell 
culture flask in the hood. It was then incubated at 37 ºC for 2-4 minutes after which 5-10 
ml of RPMI media was added to resuspend the cells and to stop the action of trypsin. The 
cells were then transferred to a 25 ml universal tube and centrifuged for 7 minutes at 1100 
rpm, 20ºC. Then 0.5 ml of freezing media (80% BEBM 10% FCS and 10% dimethyl 
sulfoxide (DMSO)) was added to the cells which were left at -80ºC for 24 hours, in 
cryotubes in a cell freezer filled with isopropanol (Nunc). Finally they were stored in 
liquid nitrogen at -180 ºC 
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2.4 Epithelial cell culture after cryopreservation   
 
 The sample was removed from liquid nitrogen and incubated at room temperature for 10 
minutes. The sample was then put in 2-3 ml of complete BEGM and mixed gently then 
added to a cell culture flask coated by 0.5% of Vitrogen (PureCol, Advanced BioMatrix, 
USA). The cells were then incubated at 37 ºC for 24 hours in a 5% CO2 atmosphere and 
the media was changed at 24 hours. After 48 hours the samples were checked under the 










2.6 Cell viability assay 
Cell viability was assessed by the Titre-blue Assay (Promega, USA) which assessed 
metabolically active cells after 48 hour incubations under experimental conditions. The 
percentages of viable cells were determined from a standard curve which was generated 
from mixtures of live and dead cells (dead cells were produced by ice cold methanol 
treatment for 5 minutes). 5 points were used to create the standard curve, 100% live cells 
resting media, 25% dead cells with 75% live cells, 50% dead cells with 50% live cells, 

















2.7 Enzyme-Linked Immunosorbent Assay (ELISA) MSD 
 
To measure cell culture supernatant IL-8, IL-6 and GMCSF, a multiplex enzyme-linked 
immunosorbent assay (ELISA) was performed using manufacturer’s instructions (Meso 
Scale Discovery, Maryland, USA). Cytokines were measured by MSD cytokine assays. 
One to four cytokines can be measured in a MSD 96-well MULTI-SPOT plate, 
competitive immunoassay (sandwich), single spot, or patterned array with capture 
antibodies (Figure 5). 
 
 
Figure 5: M-CSF Capture Antibody is pre-coated on a Single Spot MULTI-ARRAY plate 
Or on specific spots of a 4-Spot MSD MULTI-SPOT plate. Calibrator solutions and 
Samples are incubated in the plate, and M-CSF binds to corresponding Capture 
antibody spot. M-CSF is detected using an M-CSF-specific Detection Antibody labelled 
with MSD SULFO-TAGTM reagent. This figure has been modified from MSD 
 
All reagents were used at room temperature. 25 µL of diluents 2 (protein and animal 
derived material medium) was added into plates well, covered with adhesive strip and 
incubated with vigorous shaking for 30 minutes at room temperature. 25 µL of standards 
and samples were added; with vigorous shaking and incubated for 2 hours at room 
temperature. Plates were washed three times with PBS + 0.05% Tween-20 at pH 7. 
Detection antibody solution (25 µL) was added (mix 2.94 mL of diluents 3 with 60 µL 
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aliquot of the stock detection antibody) and the plates were then incubated for 2 hours at 
room temperature with vigorous shaking. A wash with wash buffer was repeated three 
times. 150 µL of read buffer was then added, and the plate was then read by the MSD 
plate reader. The lowest levels for cytokines quantitation by the MSD plate reader was 
0.6pg/mL.  
2.8 Statistical analysis 
 
GraphPad Prism version 4 for Windows was used to carry out analyses; Non-parametric 
statistical tests were used throughout on the basis that “Non-parametric” implies that there 
was no assumption of a specific distribution for the population data gathered in the thesis. 
The 1-Sample Wilcoxon was used for paired data comparisons. This is the nonparametric 
alternative to 1-sample (paired) t-tests, used when data is known to be normally 
































Lung transplantation (LTx) has attained the status of a viable therapeutic option for 
increasing survival as a treatment option for end-stage, pulmonary disorders, improving 
the quality of life (Trulock et al., 2006). The development of chronic allograft rejection is 
believed to be a significant reason for the reduced long-term survival of lung transplant 
recipients (Trulock et al., 2006). The clinical manifestation of chronic rejection is termed 
bronchiolitis obliterans syndrome (BOS) which is defined as a persistent drop after 
transplantation in the forced expiratory volume in one second (FEV1). Obliteration of the 
terminal bronchioles is the pathological cause for the development of this syndrome 
(Verleden et al., 2005). The pathophysiology of BOS is not well-understood; however, it 
is increasingly recognised that both immunological and non-immunological mechanisms 
influence it (Boehler et al., 1998, Blondeau et al., 2008b, Verleden and Dupont, 2006). A 
potential non-alloimmune cause of BOS has been identified as gastro-oesophageal reflux 
(GOR) and oesophageal pH-metry has shown a greater oesophageal acid exposure in 70% 
of LTx patients (Benden et al., 2005, Hadjiliadis et al., 2003). Pepsin and bile acids have 
been identified as important luminal gastric components present, in bronchial material of 
LTx recipients (D'Ovidio et al., 2005b, Ward et al., 2005, D'Ovidio et al., 2006a). 
D’Ovidio et al have demonstrated that increased bile acids levels in (BALF) in 22% of 
LTx patients was associated with reduced freedom from BOS (D'Ovidio et al., 2006a). 
All LTx recipients had increased levels of pepsin in BALF, suggesting that aspiration 
after LTx might be widespread even in the patients with normal GOR indices (Ward et 
al., 2005, O'Halloran et al., 2004). Bile acids have also been detected in BALF in 49% of 
LTx patients but not in the non-transplant samples (D'Ovidio et al., 2005b, D'Ovidio et 
al., 2006a). The absolute levels of BALF pepsin was thought to be a general marker of 
aspiration of gastric contents, while bile acids were found to be a more specific marker of 
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gastric aspiration, possibly related specifically to the pathophysiology of aspiration 
induced BOS. Increased oesophageal acid exposure does not seem to be discriminating, 
as similar levels have been reported in patients both with and without BOS as described 
by Davis et al and Hadjilidis et al (Davis et al., 2003a, Hadjiliadis et al., 2003) 
The potential pathophysiological, mechanistic relationships between the primary 
epithelial cells from lung recipients and the aspiration markers that have been associated 
with the development chronic rejection have been studied within this thesis. Specifically, 
the responses of primary epithelial cells have been examined when stimulated with 
different bile acids, porcine pepsin and different human gastric juice samples. The 
response of the epithelial cells has been assessed by cytokine output, concentrating on 
cytokines that are known to be involved in neutrophilia; such as interleukins 6, 8 and 
GMCSF as BOS is known to have a neutrophilic pathophysiology (Devouassoux et al., 
2002, D'Ovidio et al., 2005b).  
 
3.2 Methods and statistical analysis 
 
When PBECs were 80-95% confluent in 24 well plates they were rested for 24 hours as 
(2.2.5). After that, individual primary and secondary bile acids, porcine pepsin, and 
different patient derived gastric juice (whole, filtered and dialysed) samples were used to 
stimulate the cells. All concentrations are reported in section (2.2.5).  
 
Cell viability was assessed by the Titre-blue Assay (2.6). An MSD 96-well multiplex 
ELISA was used to measure IL-8, IL-6 and GMCSF (2.7). GraphPad Prism version 4 was 





3.3 Results and Discussion  
 3.3.1 Epithelial cell culture:  
 
One aim of my project was to process and culture primary epithelial cells from 
lung transplant recipients. Although the culture of these cells is very difficult in 
this research field, approximately 70% success rate was achieved. This experience 
was favourable compared to other studies, e.g other study success rate of 39% 
(Forrest et al., 2005)  
The cells were cultured in different culture conditions, Figure 6(A) shows 24 well 
cell cultures of primary epithelial cells from patients in complete media (BEBM) 
at 37°C. In addition, it was possible to culture cells in a 24 well cell culture to a 
defined time point (6 days), stimulate with different bile acids, porcine pepsin and 
different  human gastric juice samples (Figure 6(B)). After cryopreservation it 
was possible to re-establish these cells in culture as shown in Figure 6(C) after 
four days. Epithelial cells cultured in complete media (BEBM) in 24 well cell 
cultures and stimulated with 200 µmol/l lithocholic acid are shown in Figure 6(D) 
after 48 hours. Epithelial cells cultured in complete media (BEBM) in 24 well cell 
cultures stimulated with lithocholic acid 50 µmol/ l are shown in Figure 6(E). 
Epithelial cells cultured in complete media (BEBM) in 24 well cell cultures and 
stimulated with lithocholic acid 25 µmol/ l are shown in Figure 6(F). Epithelial 
cells cultured in complete media (BEBM) in 24 well cell cultures and stimulated 







Figure 6A: Epithelial cells cultured in complete media (BEBM) in 24 well cell cultures, at 37°C 
after three days from passage (X100 magnification). These cells have the typical appearance of 
healthy, primary epithelial cells in submerged culture. This is shown by the patches of 
‘cobblestone’ morphology. The cells are clearly adherent, with minimal numbers of floating or 






Figure 6B: Epithelial cells cultured in complete media (BEBM) of 24 well cell cultures after six 
days from passage, ready for stimulation by bile acid or vehicle alone (X100 magnification). 
As in 6 (A) these cells have the typical appearance of healthy, primary epithelial cells in 
submerged culture. This is shown by the ‘cobblestone’ morphology. The cells are clearly 
adherent, with minimal numbers of floating or fibroblast like cells. The difference between Fig 
6(A) and 6 (B) is that there are more cells and no obvious gaps. The cells are therefore confluent 









Figure 6(C): Epithelial cells cultured in complete media (BEBM) after storage in liquid 
nitrogen,cultured at 37°C, 24 well cell culture, for (6 days) (X100 magnification). As in figure 
6(A) and figure 6 (B) these cells have the typical appearance of healthy, primary epithelial cells in 
submerged culture. This is shown by the ‘cobblestone’ morphology. The cells are clearly 
adherent, with minimal numbers of floating or fibroblast like cells. The cells are therefore 
confluent and ready for stimulation experiments.  This shows that cells stored in liquid nitrogen 





Figure 6 (D): Epithelial cells cultured in complete media (BEBM) of 24 well cell cultures after 
two days of stimulation with 200 µmol/l lithocholic acid (X100 magnification). In contrast to 
Figures 6 (A) - 6 (C), these cells have lost the normal cobblestone appearance of normal healthy 







Figure 6(E): Epithelial cells cultured in complete media (BEBM) of 24 well cell cultures after 
stimulation with lithocholic acid 50 µmol/l for two days (X300 magnification). This shows 
obvious cell damage. In contrast to Figures 6(A) - 6(C) these cells have lost the normal 
cobblestone appearance of cells not incubated with lithocholic acid. Following lithocholic acid 50 
µmol/l for two days, the cells are rounded, with gaps in between cells. Cell detachment has 







Figure 6(F): Epithelial cells cultured in complete media (BEBM) of 24 well cell cultures after 
stimulation with lithocholic acid (25µmol/l) for two days (X300 magnification). The cells do not 
appear normal (i.e. some cobblestone appearance but the cells are more rounded) as in Figures 







Figure 6(G): Epithelial cells cultured in complete media (BEBM) of 24 well cell cultures after 
stimulation with lithocholic acid (1µmol/l) for two days (X300 magnification). The cells appear 
normal with an obvious cobblestone appearance and the cells are in close association with each 













A further aim of the project was to determine whether primary bronchial epithelial cells 
from lung recipients were able to produce significant increases in IL-8, IL-6 and GMCSF 
after challenge by bile acids, porcine pepsin, and different human gastric juice (whole, 
filtered and dialysed) samples as outlined in (2.2.5). 
The primary bile acid chenodeoxycholic acid and secondary bile acids deoxycholic acid 
and lithocholic acid were each used to stimulate cultured PBECs at different 
concentrations from 0.25μmol/l to 10μmol/l for 48 hours and compared to basal 
incubations. Figures 7 to 9 shows the levels of IL-8, IL-6 and GMCSF released from 
PBECs from lung transplant recipients after stimulation by chenodeoxycholic acid for 48 
hours. Table 6 shows that chenodeoxycholic acid caused a significant increase in the 
release of IL-8 at 1, 5 and 10μmol/l. However the IL-6 levels produced by the cells were 
only increase significantly by 5μmol/l chenodeoxycholic acid. GMCSF levels increased 
significantly after exposure to 0.75, 5 and 10μmol/l of chenodeoxycholic acid.  
Figures 10 to 12 show the different levels for IL-8, IL-6 and GMCSF produced after the 
challenge of PBECs with deoxycholic acid. Table 7 show that IL-8 levels at 1 and 10 
μmol/l deoxycholic acid were significantly stimulated. IL-6 levels were not elevated by 
any of the concentrations of this bile acid. Interestingly GMCSF levels were significantly 
elevated by all the concentrations of deoxycholic acid except 0.75μmol/l. Figures 13 to 15 
show the different levels for IL-8, IL-6 and GMCSF produced by PBECs after they were 
stimulated with lithocholic acid. Table 8 shows that IL-8 levels were significantly higher 
than basal at concentrations of 1 μmol/l and above of lithocholic acid. IL-6 levels were 
only elevated when stimulated by 5μmol/l lithocholic acid, GMCSF levels were 
significantly elevated by concentrations of lithocolic acid of 1μmol/l and above.  
In general these bile acid stimulation studies demonstrate that IL-6 production is the least 
effected by the bile acids with levels of 5μmol/l or above needed to achieve significant 
elevation in levels.  
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In figures 16 to 18 we can see the concentration of chenodoxycholic acid above 10µmol/l 
cause substation cell death, with 25µmol/l causing 50% cell death. 1µmol/l or above of 
deoxycholic acid and lithocholic acid also effect the cells viability, suggesting that 
secondary bile acids are more cytotoxic than primary bile acids.  
Figures 19 to 21 show the different levels of IL-8, IL-6 and GMCSF produced after 
challenge with different concentrations of porcine pepsin at pH 7.4. Those figures show 
no significant stimulation of cytokine production from PBECS from lung recipients after 
testing across a range of porcine pepsin concentrations. The pepsin used in this study 
would be inactive and probably irreversibly denatured at pH 7.4. Therefore any effect 
would be attributed to the protein and not the active enzyme. Figures 22 to 24 show the 
different levels for IL-8, IL-6 and GMCSF after challenge of PBECs with 8 different 
human gastric juices derived from patients, diluted 1:1000. The production of cytokines 
by the cells depends on which gastric juices are used (tables 8 and 9), indicating marked 
variability between different gastric juices. As shown by CR52 which produces 
significant down- regulation of IL-8 as compared to CR45 which produces significant up-
regulation of IL-8. This variability might be because of the variations in human gastric 
juice components. For example the gastric juice sample CR45 which contained no bile 
acids, and very low levels of pepsin (57µg/ml). However this particular gastric juice 
caused a significant increase in IL-8 production at 1:1000 dilution. This is potentially due 
to its content of pathogens, with α haemolytic streptococcus demonstrated on culture, 
though other organisms may also be present in the gastric juice. Interestingly this juice 
also caused a significant increase in IL-6 levels (the only juice to do so), but there was no 
significant GMCSF stimulation. The pepsin level in CR52 was much higher (1319 µg/ml) 
with no pathogens and it caused a significant down regulation of IL-8 levels. CR38 
contained 250µmol/L of total bile acids, Candida sp, A. lwoffii and α haemolytic 
streptococcus and also led to significant IL-8 stimulation, but not IL-6 or GMCSF. In 
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addition CR34 (which contained high levels of pepsin and 240µmol/l bile acids but no 
pathogens) caused a significant reduction in GMCSF levels (Table 10). Figures 25 to 27 
detail the finding that after stimulation with filtered and dialysed gastric juice samples 
PBECs produced no significant increase in levels of IL-8, IL6 and GMCSF. This may 
indicate that pathogens as well as bile acids are causing significant increases in IL-8, IL-6 
production. The whole pathogens will be removed by filtration and some bacterial 
products such as LPS (depending on size) will be removed by dialysis. Bile acids are 
mainly removed by dialysis as show in Table 9.  It is interesting to note that 4 gastric 
juice samples that had no stimulating affect on IL-6, after dialysis and filtration down 
regulated IL-6 levels. Figures 28 to 30 show that the PBECs from lung recipients were 
not significantly stimulated to produce IL-8, IL-6 or GMCSF after gastric juices were 
modified by filtration and dialysis of the samples. The comparison with the same samples 
stimulated by whole gastric juice samples indicates that the PBEC 
inflammatory/damaging components in vitro are molecules that can be removed by 




  3.4.1 IL-8, IL6 and GMSF levels, after cell stimulation with the individual primary 
bile acid (chenodoxeycholic acid) at 37 ºC for 48hours in 5% CO2. 
 
 





















Figure 7: The effect of stimulating PBECs from lung transplantation recipients with 
chenodeoxycholic acid and its effect on IL-8 release, following stimulation for 48 hours. Basal 
represents the background production of cytokine without chenodeoxycholic acid stimulation. 
Cytokine secretion in cell supernatants was measured by MSD ELISA. P values of 0.05 or less 








































Figure 8: The effect of stimulating PBECs from lung transplantation recipients with 
chenodeoxycholic acid and its effect on IL-6 release, following stimulation for 48 hours. Basal 
represents the background production of cytokine without chenodeoxycholic acid stimulation. 
Cytokine secretion in cell supernatants was measured by MSD ELISA. P values of 0.05 or less 






























Figure 9: The effect of stimulating PBECs from lung transplantation recipients with 
chenodeoxycholic acid, and its effect on GMCSF release, following stimulation for 48 hours. 
Basal represents the background production of cytokine without chenodeoxycholic acid 
stimulation Cytokine secretion in cell supernatants was measured by MSD ELISA. P values of 







 Table 6: Levels of chenodeoxycholic acid that demonstrated significant stimulation 
of cytokine release from lung transplant derived PBECS. 
 
 
 Chenodeoxycholic acid µmol/l 
0.25 0.5 0.75 1 5 10 
IL-8 _____ _____ _____ * *  * 
IL-6 _____ _____ _____ _____ * _____ 
GMCSF _____ _____ * _____ *  * 
 
Table 8: The levels of chenodeoxycholic acid challenge for PBECs from lung transplant recipient, 





















3.4.2   IL-8, IL-6 and GM-CSF levels, after cell stimulation with the individual 
secondary bile acid (Doxeycholic acid) at 37 ºC for 48hours in 5% CO2. 
 























Figure 10: The effect of stimulating PBECs from lung transplantation recipients with deoxycholic 
acid and its effect on IL-8 release, following stimulation for 48 hours. Basal represents the 
background production of cytokine without bile acid stimulation. Cytokine secretion in cell 
supernatants was measured by MSD ELISA. P values of 0.05 or less were regarded as significant. 














































Figure 11: The effect of stimulating PBECs from lung transplantation recipients with deoxycholic 
acid and its effect on IL-6 release, following stimulation for 48 hours. Basal represents the 
background production of cytokine without bile acid stimulation. Cytokine secretion in cell 
supernatants was measured by MSD ELISA. P values of 0.05 or less were regarded as significant.  


































Figure 12: The effect of stimulating PBECs from lung transplantation recipients with deoxycholic 
acid and its effect on GMCSF release, following stimulation for 48 hours. Basal represents the 
background production of cytokine without bile acid stimulation. Cytokine secretion in cell 
supernatants was measured by MSD ELISA. P values of 0.05 or less were regarded as significant.  










Table 7:  Levels of deoxycholic acid that demonstrated significant stimulation of 
cytokine release from lung transplant derived PBECS. 
 
 deoxycholic acid µmol/l 
0.25 0.5 0.75 1 5 10 
IL-8 ____ ____ ____  * ____  * 
IL-6 ____ ____ ____ ____ ____ ____ 
GMCSF  *  * ____  *  *  * 
 
Table 9: The levels of deoxycholic acid challenge for PBECs from lung transplant recipient, 






























3.4.2    IL-8, IL-6 and GM-CSF levels, after cell stimulation with the individual 
secondary bile acid (Lithocholic acid) at 37 ºC for 48hours in 5% CO2. 
 






















Figure 13: The effect of stimulating PBECs from lung transplantation recipients with lithocholic 
acid and its effect on IL-8 release, following stimulation for 48 hours. Basal represents the 
background production of cytokine without bile acid stimulation. Cytokine secretion in cell 
supernatants was measured by MSD ELISA. P values of 0.05 or less were regarded as significant.  

















































Figure 14: The effect of stimulating PBECs from lung transplantation recipients with lithocholic 
acid and its effect on IL-6 release, following stimulation for 48 hours. Basal represents the 
background production of cytokine without bile acid stimulation. Cytokine secretion in cell 
supernatants was measured by MSD ELISA. P values of 0.05 or less were regarded as significant.  
































Figure 15: The effect of stimulating PBECs from lung transplantation recipients with lithocholic 
acid and its effect on GMCSF release, following stimulation for 48 hours. Basal represents the 
background production of cytokine without bile acid stimulation. Cytokine secretion in cell 
supernatants was measured by MSD ELISA. P values of 0.05 or less were regarded as significant.  





Table 8:  Levels of lithocholic acid that demonstrated significant stimulation of 
cytokine release from lung transplant derived PBECS. 
 
 lithocholic acid µmol/l 
0.25 0.5 0.75 1 5 10 
IL-8 _____ _____ _____  * *  * 
IL-6 _____ _____ _____ _____  * _____ 
GMCSF _____ _____ _____  *  *  * 
 
Table 10: The levels of lithocholic acid challenge for PBECs from lung transplant recipient, 
























  3.4.3 Cell viability for primary bronchial epithelial cells from explanted CF 
patients after stimulation by individual bile acid 
 

















Figure 16: The viability of primary bronchial epithelial cells from lung recipients after challenge 
with different concentrations of chenodoxycholic acid for 48 hours. Cell viability was assessed by 
CellTiter- Blue cell viability assay (Promega. Madison), n=5.  
 
 

















Figure 17: The viability of primary bronchial epithelial cells from lung recipients after challenge 
with different concentrations of deoxycholic acid for 48 hours. Cell viability was assessed by 





















Figure 18: The viability of primary bronchial epithelial cells from lung recipients after challenge 
with different concentrations of lithocholic acid for 48 hours. Cell viability was assessed by 


















 3.4.4 IL-8, IL-6 and GM-CSF levels, after cell stimulation with Pepsin at 37 ºC 
 pH 7.4 for 48 hours in 5% CO2. 
 
 























Figure 19: The effect of stimulating PBECs from lung transplantation recipients with porcine 
pepsin and its effect on IL-8 release, following stimulation for 48 hours. Basal represents the 
background production of cytokine without pepsin stimulation. Cytokine secretion in cell 
supernatants was measured by MSD ELISA. P values of 0.05 or less were regarded as significant.  































Figure 20: The effect of stimulating PBECs from lung transplantation recipients with porcine 
pepsin and its effect on IL-6 release, following stimulation for 48 hours. Basal levels (no pepsin 
stimulation). Cytokine secretion in cell supernatants was measured by MSD ELISA. P values of 




























Figure 21: The effect of stimulating PBECs from lung transplantation recipients with porcine 
pepsin and its effect on GMCSF release, following stimulation for 48 hours. Basal levels (no 
pepsin stimulation). Cytokine secretions in cell supernatants were measured by MSD ELISA. P 
values of 0.05 or less were regarded as significant. The horizontal bars represent the median 




















60 Pseudomonas aeruginosa, 
Candida  parapsilosis strains 
CR34 1.6 1247 240 75 None 
CR52 1.7 1319 20 0 None 
CR47 5.1 
460 0 













0 Acinetobacter junii, Candida  
parapsilosis strains. 
CR38 6.6 0 250 40 
Candida  parapsilosis strains., 
A.lwoffii,α haemolytic 
streptococcus 
CR45 8.4 57 0 0 α haemolytic streptococcus 
 
 
Table 11: The concentration of pepsin and bile acids of each gastric juice, and the pH of the 
gastric juice sample. LTx denotes lung transplant patient and CR samples are routine 
















3.4.5 IL-8, IL-6 and GM-CSF levels, after cell stimulation with whole gastric juice at 






























Figure 22: The effect of stimulating seven different sets of PBECs from lung transplantation 
recipients with whole gastric juice diluted 1:1000 and its effect on IL-8 release, following 
stimulation for 24 hours. Basal plotted for each gastric juice. Cytokine secretions in cell 
supernatants were measured by MSD ELISA. P values of 0.05 or less were regarded as 

















































Figure 23: The effect of stimulating seven different sets of PBECs from lung transplantation 
recipients with whole gastric juice diluted 1:1000 and its effect on IL-6 release, following 
stimulation for 24 hours. Basal plotted for each gastric juice. Cytokine secretions in cell 
supernatants were measured by MSD ELISA. P values of 0.05 or less were regarded as 


































Figure 24: The effect of stimulating seven different sets of PBECs from lung transplantation 
recipients with whole gastric juice diluted 1:1000 and its effect on GMCSF release, following 
stimulation for 24 hours. Basal plotted for each gastric juice. Cytokine secretions in cell 
supernatants were measured by MSD ELISA. P values of 0.05 or less were regarded as 








Table 10: The whole diluted human gastric juice that demonstrates a significant 
effect of cytokine release. 
 
 whole gastric juice patients 1:1000 
LTx8 CR42 CR47 CR52 CR34 CR38 CR50 CR45 
IL-8 ____ ____ ____ *   *   * 
IL-6 ____ ____ ____ ____ ____ ____ ____  * 
GMCSF ____ ____ ____ ____ * ____ ____ ____ 
 
Table 12: Whole gastric juice (1:1000) challenge for PBECs from lung transplant recipient, which 
demonstrated significant changes to cytokine release.  



















3.4.6 IL-8, IL-6 and GM-CSF levels, after cell stimulation with filtered and dialysed 































Figure 25: The effect of stimulating PBECs from lung transplantation recipients with filtrated and 
dialysed gastric juice at the same 1:1000 dilution and its effect on IL-8 release, following 
stimulation for 24 hours. Cytokine secretion in cell supernatants was measured by MSD ELISA. P 
values of 0.05 or less were regarded as significant. The horizontal bars represent the median 













































Figure 26: The effect of stimulating PBECs from lung transplantation recipients with filtrated and 
dialysed gastric juice at the same 1:1000 dilution and its effect on IL-6 release, following 
stimulation for 24 hours. Cytokine secretion in cell supernatants was measured by MSD ELISA. P 
values of 0.05 or less were regarded as significant. The horizontal bars represent the median 

































Figure 27: The effect of stimulating PBECs from lung transplantation recipients with filtrated and 
dialysed gastric juice at the same 1:1000 dilutions and its effect on GMCSF release, following 
stimulation for 24 hours. Cytokine secretion in cell supernatants was measured by MSD ELISA. P 
values of 0.05 or less were regarded as significant. The horizontal bars represent the median 






Table 11:  The filtered and dialysed patient gastric juice that demonstrated a 
significant effect of cytokine release. 
 
 
 whole gastric juice patients 1:1000 
LTx8 CR42 CR47 CR52 CR34 CR38 CR50 CR45 
IL-8 ____ ____ ____ ____ ____ ____ ____ ____ 
IL-6 ____ * ____ * * * ____ ____ 
GMCSF ____ ____ ____ ____ ____ ____ ____ ____ 
 
Table 13: Whole gastric juice (1:1000) challenge for PBECs from lung transplant recipient, which 
demonstrated significant changes to cytokine release.  




















3.4.7 Comparison IL-8, IL-6 and GM-CSF levels, after cell stimulation with whole 














Whole diluted gastric juice












Figure 28: The effect of stimulating PBECs from lung transplantation recipients with whole 
gastric juice at the same 1:1000 dilution, filtered and dialysed gastric juice, its effect on IL-8 
release, following stimulation for 24 hours. Cytokine secretions in cell supernatants were 
measured by MSD ELISA. The resulte shown are mean & SEM from experiments, n=7, 




















Whole diluted gastric juice











Figure 29: The effect of stimulating PBECs from lung transplantation recipients with whole 
gastric juice at the same 1:1000 dilution, filtered and dialysed gastric juice, its effect on IL-6 
release, following stimulation for 24 hours. Cytokine secretions in cell supernatants were 
measured by MSD ELISA. The results shown are mean & SEM from experiments, n=7, 










Whole gastric diluted juice













Figure 30: The effect of stimulating PBECs from lung transplantation recipients with whole 
gastric juice at the same 1:1000 dilution, filtered and dialysed gastric juice, its effect on GMCSF 
release, following stimulation for 24 hours. Cytokine secretions in cell supernatants were 
measured by MSD ELISA. The results shown are mean & SEM from experiments, n=7, 






Primary epithelial cells from lung transplant recipients were cultured, passaged and stored 
in liquid nitrogen, this method helped with the research because it allowed me to repeat 
experiements, and find the same sample to culture again after storage. PBECs stimulated 
with bile acids indicated the potential for a number of bile acids to cause inflammatory 
cytokine production with the hydrophobic lithocholic acid being particularly potent on a 
molar basis as can be seen with the cell viability data. 
However, there was no significant cytokine release from PBECs, after stimulation with 
various concentrations of porcine pepsin (25-100 ng/ml). 
Human gastric juices can stimulate inflammatory cytokine production from PBECs at 
potentially physiologically achievable dilutions (1:1000), i.e levels of gastric juice that 
could potentially be found in the lung. Filtration and dialysis of gastric juices indicate that 
a significant portion of the gastric juices’ stimulatory potential is of small molecular 
weight origin such as bile acids. 
The potential for microbiological content of gastric juice to be a stimulating factor was 
implied by the fact that gastric juice samples grew a range of bacteria and that the 
stimulatory potential of gastric juice was modifiable by filtration.  
There are some study that suggests a relationship between bile acid structure and effect on 
PBECs in vitro (Resarcher, 2008). It may be that hydroxyl groups play a role in 
stimulation, as chenodeoxycholic acid and deoxycholic acid have two hydroxyl groups 
and were shown to be less toxic and also did not make PBECs produce significant levels 
of cytokines. Whereas lithocholic acid has one OH group and is more toxic to PBECs. 
Lithocholic acid caused significant stimulation of IL-8 and GMCSF with concentration of 
1µmol/l and above.  
Pepsin at pH 7.4 was found to have no effect on PBECs in vitro and did not cause 
significant stimulation of IL-8 IL-6 and GMCSF. At pH 7.4, pepsin is not active and 
cannot cause damage to the extracellular matrix of the lung tissues in vitro. Mertens et al, 
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suggest no relationship between concentration of pepsin and IL-8 released from PBECs in 
vitro (Mertens et al., 2010)    
A hypothesis for the down regulation of inflammatory response would be the presence of 
Helicobacter pylori in gastric juice which has been shown to increase the production of 
IL-10 which can dampen the immune response (Bodger and Crabtree, 1998). Although 
the bacteria would be removed by filtration its endotoxins, vacuolating cytotoxin A 
(VacA), would not be. VacA is secreted and processed as a 33k and a 55k protein. These 
can induce apoptosis and down regulation of cellular activity (Isomoto et al., 2010). There 
was no effect on cell viability after stimulation with porcine pepsin, whole diluted human 





























 4.1 Introduction 
 
Defects in the cystic fibrosis transmembrane conductance regulator (CFTR) gene have 
been identified as the causal mechanism for cystic fibrosis (CF). Chronic CF leads to life-
long morbidity and premature mortality (Ratjen, 2009). Lung disease accounts for more 
than 95% of morbidity and mortality in CF patients (Doring et al., 2007, Ratjen, 2009). 
During recent decades, promising improvements in the clinical care practices have led to 
an improved rate of survival for people suffering from CF, however knowledge about the 
exact pathogenesis of CF lung disease continues to be limited (Dodge et al., 2007).  
Intense neutrophilic inflammation has been found to be a key histological characteristic of 
the CF airway, it is also well known that interleukin (IL-8) is a dominant cytokine in CF 
lung disease (Downey et al., 2009). Children and adults with CF have been reported to 
suffer from gastro-oesophageal reflux, however, the exact contribution of reflux to lung 
injury has not been evaluated extensively. The prevalence of reflux has been estimated 
between 55 to 90% (Blondeau et al., 2008a, Brodzicki et al., 2002, Button et al., 2005, 
Gustafsson et al., 1991, Heine et al., 1998, Ledson et al., 1998, Malfroot and Dab, 1991, 
Scott et al., 1985, Vic et al., 1995). It has been emphasized that certain primary and 
secondary mechanisms make CF patients prone to reflux. These mechanisms include 
reduced lower oesophageal sphincter pressure, increased transient lower oesophageal 
sphincter relaxations, delayed gastric emptying and altered abdominal-thoracic pressure 
dynamics during coughing and chest physiotherapy (Ledson et al., 1998, Cucchiara et al., 
1991, Blondeau et al., 2008a). Reduced lung function in people with CF has been 
associated with the presence of reflux-induced cough (Blondeau et al., 2008a) and gastro-
oesophageal reflux (Navarro et al., 2001, Blondeau et al., 2008a). 
Another common finding in people with CF is abnormal gastrointestinal motility leading 
to reflux of duodenal contents back into the stomach (Hallberg et al., 2004). In line with 
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this observation, sputum of both adults and children with CF has been analyzed and found 
to contain high concentrations of bile acids (Blondeau et al., 2008a, Blondeau et al., 
2010). Lung transplant recipients transplanted for CF have also been found to have higher 
concentration of bile acids in bronchoalveolar lavage (BAL) fluid, compared to non-CF 
lung transplant recipients and non-transplant controls (Blondeau et al., 2008a). It must be 
noted however, that non- or weakly-acidic refluxate, is more likely to be clinically silent, 
and therefore, under recognised. In order to detect it, oesophageal impedance is required 
in addition to pH monitoring alone (Sweet et al., 2009, Blondeau et al., 2008a). The 
present state of understanding about non-acidic reflux and aspiration in lung injury is 
limited and appropriate studies are warranted. The underlying hypothesis was that people 
with CF would have bile acids present in the lower airways and that bile acid challenge 
would cause release of inflammatory mediators and damage to primary bronchial 
epithelial cells (PBECs) cultured from CF lungs. 
 
 4.1.1 Method and Statistical analysis 
 
CF lung derived PBEC cultures were used to perform proof of concept experiments. In 
these experiments the affect of individual primary and secondary bile acids, porcine 
pepsin, different patient derived gastric juice (whole or filtered and dialysed) samples and 
an artificial bile acid mixture (similar to that found in human bile) were evaluated. All 
concentrations are shown in section (2.2.5).  
  
Cell viability was assessed by the Titre-blue Assay (2.6). An MSD 96-well multiplex 
cytokine kit was used to measure IL-8, IL-6 and GMCSF (2.7). GraphPad Prism version 4 
was used for analysis of data as outlined in (2.8). 
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4.2 Results and Discussion   
    
One of the project aims was to process and culture primary epithelial cells PBECs 
from the explanted lung of CF patients. Initial cultures were produced from CF lungs 
by Dr Malcolm Brodlie. Subsequently, an approximately 70% success rate was 
achieved for ongoing culture due to the methods developed (Brodlie et al., 2010). 
Another aim of the project was to establish whether primary epithelial cells PBECs 
from CF patients (CF PBECs) are able to produce significant increases in IL-8, IL-6 
and GMCSF after stimulation with bile acids, porcine pepsin different human gastric 
juice (whole, filtered and dialysed) samples (Table 9) dilutions 1:1000 and a bile acid 
mixture (2.2.5)     
The levels for inflammatory cytokine production IL-8, IL-6 and GMCSF from primary 
epithelial cells from explanted CF patients after stimulated by chenodeoxycholic acid for 
48 hours are shown in Figures 31 to 33. Table 12 shows that chenodeoxycholic acid 
caused a significant increase in the release of IL-8 at 0.25, 0.5, 0.75, 1, 5 and 10µmol/l 
compared to basal levels. The IL-6 response threshold was higher than the IL-8 response 
becoming significant at 1µmol/l and 5µmol/l but not at 10µmol/l. The threshold for the 
GMCSF response was similar to IL-6 where significantly higher levels did not occur until 
the cells were exposed to concentration of 1µmol/l and above of chenodoxycholic acid. 
Figures 34 to 36 show the different levels for IL-8, IL-6 and GMCSF release from CF 
PBECs after being challenged with deoxycholic acid for 48 hours. Table 13 shows a 
significant increase in IL-8 levels at 0.25, 0.5, 0.75, 1, 5 and 10µmol/l deoxycholic acid. 
Concentration 1, 5 and 10µmol/l made CF PBECs release significantly higher levels of 
IL-6. Table  13 and figure 36 show that GMCSF release was significantly up regulated by 
levels of 1µmol/l and above of deoxycholic acid.  Figures 37 to 39 show the levels for IL-
8, IL-6 and GMCSF released from CF PBECs after stimulation with lithocholic acid for 
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48 hours. Table 14 shows that IL-8 levels at 0.25, 0.5, 0.75, 1, 5 and 10µmol/l are 
significantly different from basal. IL-6 and GMCSF levels are significantly elevated with 
lithocholic acid at concentrations of 1, 5 and 10µmol/l. These results demonstrate that the 
IL-8 cytokine response is invoked at much lower bile acid concentration than IL-6 and 
GMCSF. Cell viability for CF PBECs after stimulation with individual bile acids are 
shown in figures 40 to 42. Concentrations above 25µmol/l of chenodeoxycholic acid and 
deoxycholic acid cause 17 and 20 % cell death respectively, but with lithocholic acid the 
effects on cell viability at concentrations above 25µmol/l increased cell death to 55 %.   
Figures 43 to 45 show the levels for IL-8, IL-6 and GMCSF after the cells were 
stimulated with different concentrations of porcine pepsin at pH 7.4. There was non-
significant increase in IL-8 cytokine production from CF PBECs with no effect on IL-6 or 
GMCSF at concentrations of 25, 50 and 100 ng/ml of porcine pepsin. Figures 46 to 48 
have shown the different levels of IL-8, IL-6 and GMCSF production after challenges 
with 8 different whole diluted human gastric juice samples. The cytokine production by 
the cells depends on which gastric juices used (Table 9), indicating marked variability 
between different gastric juices, and the variations in the whole human gastric juice 
components. IL-8 levels were significantly increased on exposure to four 1:1000 diluted 
gastric juices CR42, CR47, CR34 and CR38. Three out of four of these gastric juices also 
increased the levels of IL-6 but none of the gastric juices significantly altered GMCSF 
levels as seen in table 15. For example, the gastric juice sample CR47 which contained 
moderate levels of pepsin (460µg/ml) but no bile acids caused a significant increase in 
IL-8 production at 1:1000 dilution. This is potentially due to its content of pathogens, 
with P. Mirabilis, K. ozaenae demonstrated on culture (Table 9), though other organisms 
may be present in the gastric juice. The other three juices (CR 34, 38 and 42) that 
significantly increase IL-8 levels all contain bile acids ranging from 240 - 480µmol/l. 
CR34 and CR42 also contain pepsin activity, 1247µg/ml and 3153µg/ml respectively. 
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Pathogens were identified in CR38 and CR42 but not in CR34. This suggests that one of 
the above factors or a combination of them stimulates IL-8 release / production. 
Interestingly CR34 does not significantly stimulate IL-6 release and it does not contain 
any pathogens. This suggests that the IL-6, unlike the IL-8 response requires pathogens to 
be present in the gastric juice.  
 CF PBECs produced no significant increase of IL-8, IL-6 and GMCSF after stimulation 
with filtered and dialysed diluted human gastric juice samples. 
There appears to be significant changes in IL-6 levels with the dialysed filtered gastric 
juices, with several showing a reduction in IL-6 levels. These were not considered further 
because the differences were close to the limit of quantisation of the ELISA for IL-6 i.e. 
0.6pg/ml. A comparison of whole, filtered and dialysed gastric juices are provided in 
figure 52, 53 and 54 for IL-8, IL6 and GMCSF changes. Dialysis and filtration has 
removed the factors responsible for the induced changes to cytokine levels. 
 Figures 55, 56 and 57 show there is no significant changes in the levels of IL-8, IL-6 and 
GMCSF from CF PBECs after stimulation with an artificial bile acid mixture. IL-8 shows 
an upward trend and IL-6 and GMCSF a downward trend. It is surprising considering that 
the bile acid mixture had no effect on cytokine production considering that individual bile 
acids produce increases in cytokine output at levels below 10µmol/l (the concentration of 
the bile acid mixture). Porcine pepsin, different whole / filtered and dialysed diluted 
human gastric juice samples and bile acid mixture showed no significant effect on cell 








  4.2.1 IL-8, IL-6 and GM-CSF levels, after cell stimulation with the individual 
primary bile acid (chenodoxeycholic acid) at 37 ºC for 48hours in 5% CO2. 
 
 





















Figure 31: The effect of stimulating PBECs from explanted CF patients with chenodeoxycholic 
acid and its effect on IL-8 release, following stimulation for 48 hours. Basal represents the 
background production of cytokine without chenodeoxycholic acid stimulation. Cytokine 
secretion in cell supernatants was measured by MSD ELISA. P values of 0.05 or less were 











































Figure 32: The effect of stimulating PBECs from explanted CF patients with 
chenodeoxycholic acid and its effect on IL-6 release, following stimulation for 48 hours. 
Basal represents the background production of cytokine without chenodeoxycholic acid 
stimulation. Cytokine secretion in cell supernatants was measured by MSD ELISA. P 
values of 0.05 or less were regarded as significant. The horizontal bars represent the 
median values from experiments, n=10. 
 


























Figure 33: The effect of stimulating PBECs from explanted CF patients with 
chenodeoxycholic acid, and its effect on GMCSF release, following stimulation for 48 
hours. Basal represents the background production of cytokine without chenodeoxycholic 
acid stimulation. Cytokine secretion in cell supernatants was measured by MSD ELISA. P 
values of 0.05 or less were regarded as significant. The results shown are median values 





Table 12:  Levels of chenodeoxycholic acid that demonstrated significant stimulation 
of cytokine release. 
 
 
 Chenodeoxycholic acid µmol/l 
0.25 0.5 0.75 1 5 10 
IL-8  * *  *  *  *  * 
IL-6 ____ ____ ____  *  * ____ 
GMCSF ____ ____ ____  *  *  * 
 
 
Table 14: The levels of chenodeoxycholic acid challenge for PBECs from explanted CF patients 























4.2.2   IL-8, IL-6 and GM-CSF levels, after cell stimulation with the individual 


























Figure 34: The effect of stimulating PBECs from explanted CF patients with deoxycholic 
acid and its effect on IL-8 release, following stimulation for 48 hours. Basal represents 
the background production of cytokine without bile acid stimulation. Cytokine secretion 
in cell supernatants was measured by MSD ELISA. P values of 0.05 or less were regarded 






































Figure 35: The effect of stimulating PBECs from explanted CF patients with deoxycholic 
acid and its effect on IL-6 release, following stimulation for 48 hours. Basal represents 
the background production of cytokine without bile acid stimulation. Cytokine secretion 
in cell supernatants was measured by MSD ELISA. P values of 0.05 or less were regarded 
as significant. The results shown are median values from experiments, n=10 
 


























Figure 36: The effect of stimulating PBECs from explanted CF patients with deoxycholic 
acid and its effect on GMCSF release, following stimulation for 48 hours. Basal 
represents the background production of cytokine without bile acid stimulation. Cytokine 
secretion in cell supernatants was measured by MSD ELISA. P values of 0.05 or less 









 deoxycholic acid µmol/l 
0.25 0.5 0.75 1 5 10 
IL-8  *  * *  * *  * 
IL-6 ____ ____ ____  *  *  * 
GMCSF ____ ____ ____  *  *  * 
 
Table 15: The levels of deoxycholic acid challenge for PBECs from explanted CF patients for 48 



























4.2.3   IL-8, IL-6 and GM-CSF levels, after cell stimulation with the individual 
secondary bile acid (Lithocholic acid) at 37 ºC for 48hours in 5% CO2. 
 
 
























Figure 37: The effect of stimulating PBECs from explanted CF patients with lithocholic 
acid and its effect on IL-8 release, following stimulation for 48 hours. Basal represents 
the background production of cytokine without bile acid stimulation. Cytokine secretion 
in cell supernatants was measured by MSD ELISA. P values of 0.05 or less were regarded 







































Figure 38: The effect of stimulating PBECs from explanted CF patients with lithocholic 
acid and its effect on IL-6 release, following stimulation for 48 hours. Basal represents 
the background production of cytokine without bile acid stimulation. Cytokine secretion 
in cell supernatants was measured by MSD ELISA. P values of 0.05 or less were regarded 
as significant. The horizontal bars represent the median values from experiments, n=10. 
 
 






























Figure 39: The effect of stimulating PBECs from explanted CF patients with lithocholic 
acid and its effect on GMCSF release, following stimulation for 48 hours. Basal 
represents the background production of cytokine without bile acid stimulation. Cytokine 
secretion in cell supernatants was measured by MSD ELISA. P values of 0.05 or less 











 lithocholic acid µmol/l 
0.25 0.5 0.75 1 5 10 
IL-8  *  *  *  *  *  * 
IL-6 ____ ____ ____  *  *  * 
GMCSF ____ ____ ____  *  *  * 
 
 
Table 16: The levels of lithocholic acid challenge for PBECs from explanted CF patients 48 
hours, which demonstrated significant stimulation of cytokine release.  
      Increase 

























4.2.4   Cell viability for primary bronchial epithelial cells from explanted CF 
patients after stimulation by individual bile acid.  
 















Figure 40: The viability of primary bronchial epithelial cells from explanted CF patients after 
challenge with different concentrations of chenodoxycholic acid for 48 hours. Cell viability was 
assessed by CellTiter- Blue cell viability assay (Promega. Madison), n=5.  
 
 















Figure 41: The viability of primary bronchial epithelial cells from explanted CF patients after 
challenge with different concentrations of deoxycholic acid for 48 hours. Cell viability was 





















Figure 42: The viability of primary bronchial epithelial cells from explanted CF patients after 
challenge with different concentrations of lithocholic acid for 48 hours. Cell viability was 














 4.2.5 IL-8, IL-6 and GM-CSF levels, after cell stimulation with pepsin at 37 ºC    
(pH 7.4) for 48hours in 5% CO2. 
 
  


















Figure 43: The effect of stimulating PBECs from explanted CF patients with porcine 
pepsin and its effect on IL-8 release as a log plot (log 10), following stimulation for 48 
hours. Basal represents the background production of cytokine without pepsin 
stimulation. Cytokine secretion in cell supernatants was measured by MSD ELISA. P 
values of 0.05 or less were regarded as significant. The results shown are median values 




























Figure 44: The effect of stimulating PBECs from explanted CF patients with porcine 
pepsin and its effect on IL-6 release as a log plot (log 10), following stimulation for 48 
hours. Basal represents the background production of cytokine without pepsin 
stimulation. Cytokine secretion in cell supernatants was measured by MSD ELISA. P 
values of 0.05 or less were regarded as significant. The results shown are median values 
from experiments, n=4. 
 
 






















Figure 45: The effect of stimulating PBECs from explanted CF patients with porcine 
pepsin and its effect on GMCSF release, following stimulation for 48 hours. Basal 
represents the background production of cytokine without pepsin stimulation. Cytokine 
secretion in cell supernatants was measured by MSD ELISA. P values of 0.05 or less 




4.2.6 IL-8, IL6 and GMSF levels, after cell stimulation with whole gastric juice at 37 

































Figure 46: The effect of stimulating seven different sets of PBECs from explanted CF 
patients with whole gastric juice diluted 1:1000 and its effect on IL-8 release, following 
stimulation for 24 hours. Basal plotted for each gastric juice. Cytokine secretions in cell 
supernatants were measured by MSD ELISA. P values of 0.05 or less were regarded as 






































p=0.03 p=0.68 p=0.15 p=0.03
p=0.84
p=0.06










Figure 47: The effect of stimulating seven different sets of PBECs from explanted CF 
patients with whole gastric juice diluted 1:1000 and its effect on IL-6 release as a log plot 
(log 10), following stimulation for 24 hours. Basal plotted for each gastric juice. Cytokine 
secretions in cell supernatants were measured by MSD ELISA. P values of 0.05 or less 





































Figure 48: The effect of stimulating seven different sets of PBECs from explanted CF 
patients with whole gastric juice diluted 1:1000 and its effect on GMCSF release as a log 
plot (log 10), following stimulation for 24 hours. Basal plotted for each gastric juice. 
Cytokine secretions in cell supernatants were measured by MSD ELISA. P values of 0.05 









 whole gastric juice patients diluted 1:1000 
LTx8 CR42 CR47 CR52 CR34 CR38 CR50 CR45 
IL-8 ____  *  * ____  *  * ____ ____ 
IL-6 ____  *  * ____ ____  * ____ ____ 
GMCSF ____ ____ ____ ____ ____ ____ ____ ____ 
 
Table 17: The patients diluted whole gastric juice challenge for PBECs from explanted CF 





















4.2.7 IL-8, IL-6 and GM-CSF levels, after cell stimulation with filtered and dialysed 





























Figure 49 : The effect of stimulating PBECs from explanted CF patients with filtered and 
dialysed human gastric juice at the same 1:1000 dilution and its effect on IL-8 release as a 
log plot (log 10), following stimulation for 24 hours. Cytokine secretion in cell 
supernatants was measured by MSD ELISA. P values of 0.05 or less were regarded as 













































Figure 50: The effect of stimulating PBECs from explanted CF patients with filtered and 
dialysed human gastric juice at the same 1:1000 dilution and its effect on IL-6 release as a 
log plot (log 10), following stimulation for 24 hours. Cytokine secretion in cell 
supernatants was measured by MSD ELISA. P values of 0.05 or less were regarded as 














p=0.84 p=0.68 p=0.03 p=0.03 p=0.03 p=0.56
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Figure 51: The effect of stimulating PBECs from explanted CF patients with filtered and 
dialysed human gastric juice at the same 1:1000 dilution and its effect on GMCSF release 
as a log plot (log 10), following stimulation for 24 hours. Cytokine secretion in cell 
supernatants was measured by MSD ELISA. P values of 0.05 or less were regarded as 






4.2.8 Comparison IL-8, IL-6 and GM-CSF levels, after cell stimulation with whole, 










Whole diluted gastric juice











Figure 52: The effect of stimulating PBECs from explanted CF patients with whole, 
filtrated and dialysed gastric juice at the same 1:1000 dilution, its effect on IL-8 release as 
a log plot (log 10), following stimulation for 24 hours. Cytokine secretion in cell 
supernatants was measured by MSD ELISA. The resulte shown are mean & SEM values 















Whole diluted gastric juice









Figure 53: The effect of stimulating PBECs from explanted CF patients with whole, 
filtrated and dialysed gastric juice at the same 1:1000 dilution, its effect on IL-6 release as 
a log plot (log 10), following stimulation for 24 hours. Cytokine secretion in cell 
supernatants was measured by MSD ELISA. The resulte shown are mean & SEM values 
from experiments, n=6. 
 
 




Whole diluted gastric juice













Figure 54: The effect of stimulating PBECs from explanted CF patients with whole, 
filtrated and dialysed gastric juice at the same 1:1000 dilution, its effect on GMCSF 
release as a log plot (log 10), following stimulation for 24 hours. Cytokine secretion in 
cell supernatants was measured by MSD ELISA. The resulte shown are mean & SEM 





4.2.9 IL-8, IL-6 and GM-CSF levels, after cell stimulation with bile acids mixture, at 
37 ºC for 48 hours in 5% CO2. 
 
 
















Figure 55: The effect of stimulating PBECs from explanted CF patients with bile acids 
mixture, its effect on IL-8 release, following stimulation for 48 hours. Cytokine secretion 
in cell supernatants was measured by MSD ELISA. P values of 0.05 or less were regarded 




























Figure 56: The effect of stimulating PBECs from explanted CF patients with bile acids 
mixture, its effect on IL-6release, following stimulation for 48 hours. Cytokine secretion 
in cell supernatants was measured by MSD ELISA. P values of 0.05 or less were regarded 
as significant. The results shown are median values from experiments, n=12. 
 
 





















Figure 57: The effect of stimulating PBECs from explanted CF patients with bile acids 
mixture, its effect on GMCSF release, following stimulation for 48 hours. Cytokine 
secretion in cell supernatants was measured by MSD ELISA. P values of 0.05 or less 







Experiments with primary epithelial cells from explanted lung of CF patients have 
demonstrated an increase in the release of the key inflammatory mediators IL-8 and IL-6 
caused by physiologically achievable levels of individual primary and secondary bile 
acids as well as different patient derived gastric juice (whole, filtered and dialysed) 
diluted samples. It was of interest that porcine pepsin and an artificial bile acid mixture 
had no effect on cytokine production. The lack of effect by porcine pepsin may be related 
to the pH of the incubation (that was 7.4). Pepsin is inactive at this pH and activity may 
be necessary for a cytokine related effect. The lack of an effect of the bile acid mixture is 
more difficult to explain when considering its concentration. This mixture (10µmol/l) is 
made up of two conjugated bile acids, 50% taurocholic acid, 15% taurodeoxycholic acids, 
one primary and one secondary. In addition the mixture contains two free bile acids, one 
primary (30% chenodeoxycholic acid) and one secondary (5% lithocholic acid). 
Consequently taurocholic acid, taurodeoxycholic acid will be present at 5µmol/l, and 
1.5µmol/l respectively. Chenodeoxycholic acid and lithocholic acid would be present at 
3µmol/l and 0.5µmol/l.  
Chenodeoxycholic acid has been show in figures 31-33 to upregulate IL-8 production at 
0.25µmol/l, and also IL-6 and GMCSF at 1µmol/l, so it is present in the mixture at high 
enough levels to produce stimulation of all the cytokines. Lithocholic acid upregulates IL-
8 production at 0.25µmol/l and also IL-6 and GMCSF at 1µmol/l (figures 37-39), so it is 
present at a high enough concentration to significantly increase IL-8 but not IL-6 or 
GMCSF levels. It is possible that the lack of stimulating effect of the mixture is because 
the conjugated bile acids are having an inhibitory effect. This would be something for 
future research to address and to determine if it is related to differences in the solubility 
and hydrophobicity of the bile acids (Pearson et al., 2011)    
112 
 
Importantly, these findings suggest that duodeno-gastro-oesophageal reflux and 
subsequent microaspiration may contribute to the neutrophilic inflammation that is the 
distinctive hallmark of CF lung disease (Hallberg et al., 2004).  
 IL-8 levels were significantly elevated by all the individual bile acids, and at all 
concentration used.  Higher concentrations of bile acids were required to upregulate IL-6 
and GMCSF levels suggesting that these CF airway epithelial cells have an IL-8 
phenotype in terms of inflammatory cytokine production. This phenotype may well be a 
characteristic of most epithelial cells as human gingival epithelial cells respond to 
bacterial stimuli with a 7 fold greater IL-8 output composed to IL-6 (Stathopoulou et al., 
2010). 
Some of the whole diluted human gastric juices were able to cause an increase in IL-8 
production by CF PBECs but this was dependent on the components of the juice. After 










The effect of refluxate components on the mucus secreting goblet cell 




































The role of the bronchial epithelium in the pathogenesis of various pulmonary disease 
states has been extensively researched during the last decade. As in the skin and 
gastrointestinal tract, epithelial cells form the lining of the entire respiratory tract and 
remain continually exposed to the external environment.  
Traditionally the bronchial epithelium was believed to be a physical barrier to inhaled 
irritants and noxious substances; as such it was assumed to have a mechanical function of 
propelling tracheobronchial secretions toward the pharynx. However, it is well 
documented that the bronchial epithelium as well as acting as a physicochemical barrier 
may also play a crucial role in initiating and augmenting pulmonary host defence 
mechanisms. This defensive mechanism includes the synthesis and release of a variety of 
mediators that can cause inflammatory cell differentiation, chemotaxis, and activation 
during both health and disease. There are many types of epithelial cells within the 
airways, of which columnar, ciliated and goblet cells are the most prominent in the large 
and intermediate sized airways. Other subtypes include serous, basal, clara and 
neuroendocrine cells. The different characteristics of these cells contribute to the 
complicated functionality of the bronchial epithelium (Davies and Devalia, 1992, Mills et 
al., 1999). Transepithelial electrolyte transport and propelling of tracheobronchial 
secretions toward the pharynx is carried out by ciliated cells. Synthesis of mucin and 
formation of a viscoelastic blanket of mucus that covers much of the bronchial epithelium 
is the function of goblet and serous cells (Mills et al., 1999). The pseudostratified 
appearance of the epithelium is because of the presence of basal cells which are also 
involved in the attachment of superficial cells to the basal membrane. Basal cells have 
been suggested as the precursors to the other epithelial cell types within the airways. 
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Distal airways contain numerous clara cells which have an active role in the production of 
surfactant at these sites. The specific roles of the other epithelial cell types are less well 
understood but evidence exists that they could be involved in cell-to-cell signalling 
processes.  
Bronchial epithelial cells have been linked with the synthesis and release of a variety of 
proinflammatory cytokines involved in airway inflammation and epithelial damage 
(Hamid et al., 1993, Mills et al., 1999). In addition, development of airflow obstruction in 
both asthma and chronic obstructive pulmonary disease (henceforth referred to as COPD) 
has been linked to endothelins, which are peptides that have been noted for causing 
profound vaso- and bronchoconstriction (Howarth et al., 1995). Similarly, mediators such 
as the cysteinyl leukotrienes, derived from metabolism of arachidonic acid, have been 
shown to be capable of causing smooth muscle contraction, effecting cell chemo-
attraction, changes in vascular permeability, and excessive production of mucus  
(Howarth et al., 1995)  
The relationship between the production of proinflammatory cytokines by the airway 
epithelium and allergic conditions such as asthma and allergic rhinitis has been widely 
studied and it has been established that these compounds influence the activity of 
inflammatory cells such as eosinophils, T lymphocytes, and mast cells, all of which are 
the typical infiltrating cells in these disorders (Djukanovic et al., 1990, Corrigan and Kay, 
1991). More recently, interest has been steadily growing in the study of the role of airway 
epithelial cell-derived pro-inflammatory  cytokines in the pathogenesis of nonallergic 
airway conditions, such as chronic bronchitis and COPD (Adachi et al., 1997, Becker et 
al., 1997, Khair et al., 1995, Devalia et al., 1993, Wang et al., 1996).  
This chapter evaluates whether the goblet cell line MTX 29 can produce a variety of 
cytokines, both constitutively and after stimulation with different bile acids, porcine 




5.2 Method and Statistical analysis 
 
When the HT29 MTX goblet cells were 80-90% confluent in 24 well plates, they were 
rested for 24 hours in serum free medium as stated in 2.2.5. The cells were then 
stimulated with individual primary and secondary bile acids, porcine pepsin, different  
human gastric juice (whole, filtered and dialysed) samples and a bile acid mixture at 
concentrations as shown in section 2.2.5.  
 
The Titre-blue assay was used to assess Cell viability (2.6). IL-8, IL-6 and GMCSF were 
measured by using a MSD 96-well (2.7). Analysis of data was by GraphPad Prism 

















5.3 Results and Discussion   
 
 An aim of this project was to process and culture a human goblet cell line. 
Approximately 90% success rate for cell culture was achieved during this projecy. 
The cells were cultured under different conditions. Figure 58 (A) shows 24 well cell 
cultures of the goblet cells in complete media (DMEM) at 37°C with high CO2 
(10%). 
 In addition, it was possible to culture cells in a 24 well cell culture and to stimulate 
them with different bile acids, porcine pepsin, different gastric juice samples was well 
as a ‘physiological’ mixture of bile acids (figure 58 (B)). After cryopreservation, it 
was possible to re-establish these cells in culture. These cells have the typical 
appearance of healthy, goblet cell line HT-29 MTX in submerged culture, which is 
shown by the ‘cobblestone’ morphology. The cells are clearly adherent with minimal 





















Figure 58(A): Goblet cell line cultured in complete media (DMEM) in 24 well cell cultures, at 
37°C with 10% CO2 for 96 hours (x200 magnification). These cells have the typical appearance of 
healthy, goblet cell line HT-29 MTX in submerged culture. This is shown by the ‘cobblestone’ 
morphology and the cells appear more rounded than PEBCs. The cells are clearly adherent, with 





Figure 58(B): Goblet cell line cultured in 24 well cell cultures for stimulation experiments at 37°C 
with 10% CO2 for 96 hours (x300 magnification). These cells have the typical appearance of 
healthy, primary epithelial cells in submerged culture. This is shown by the ‘cobblestone’ 
morphology. The cells are clearly adherent, with minimal numbers of floating or fibroblast like 
cells. The difference between Figure 58(A) and 58 (B) is that the cells are clearly confluent and  










Another aim of this project was to establish whether the goblet cell line HT-29 MTX was 
able to produce significant changes in IL-8, IL-6 and GMCSF levels after exposure to bile 
acids, porcine pepsin, different diluted (1:1000) human gastric juice samples (whole, 
filtered and dialysed) and bile acid mixture (2.2.5) as seen in Table 9. 
The levels of inflammatory cytokine production were measured for IL-8, IL-6 and 
GMCSF from the goblet cell line HT- 29 MTX after stimulation with different 
concentrations between 0.25μmol/l and 10μmol/l for 48 hours with the primary bile acid 
chenodeoxycholic acid. IL-8 basal output was similar (≈ 3000pg/ml) to PBECs. However, 
the IL-6 and GMCSF produced by HT-29 MTX were lower (max 10pg/ml for both) than 
PBECs basal GMCSF and basal IL-6 (≈ 200 pg/ml and ≈ 80 pg/ml respectively), again 
this is evidence of an IL-8 phenotype. Figures 59 to 61 are shown that compared to basal, 
IL-8, IL-6 and GMCSF levels varied after exposure to chenodeoxycholic acid with 
sometimes an increase and sometimes a decrease, however none of the changes were 
significant. 
Figures 62 to 64 shown the levels for IL-8, IL-6 and GMCSF released from HT-29 MTX 
cells after stimulation with the secondary bile deoxycholic acid. Similarly to 
chenodeoxycholic acid the levels of IL-8, IL-6 and GMCSF varied after exposure to 
deoxycholic acid with sometimes an increase and sometimes a decrease, however none of 
the changes were significant. Figures 65 to 67 show HT-29 MTX cells were unable to 
release any significantly different levels of IL-8, IL-6 and GMCSF after treatment with 
different concentrations of lithocholic acid (0.25μmol/l to 10μmol/l) over a 48 hour 
period. Overall the goblet cell line was unresponsive in terms of cytokine release when 
exposed to primary and secondary bile acids at concentrations up to 10µmol/l. Figures 68 
to 70 show that exposure of the goblet cell line for 48 hours to porcine pepsin (25 to 
100ng/ml) caused a non significant decrease in IL-8 release and has no significant effect 
on IL-6 or GMCSF release.  
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Figures 71 to 72 and Table 16 show that the goblet cell line HT-29 MTX was able to 
release significantly increased levels from IL-8 after stimulation with diluted (1:1000) 
whole human gastric juices from certain patients (LTx8, CR47, CR52, CR34, CR38, 
CR50 and CR45), however CR42 did not. All of the diluted human gastric juice samples 
have different amounts of pepsin, total bile acid, a different pH and different pathogen 
microbiology (Table 9). It seems unlikely that pepsin levels or presence of pathogens are 
causing this increase in IL-8 levels. As CR42 which does not invoke an increase has the 
second highest bile acid and pepsin content and contains Acinetobacter junii and Candida 
parapsilosis strains. IL-6 levels are significantly increased by gastric juices CR47, CR52 
and CR34, however the levels measured (shown in Figure 72) are below the limit of 
accurate quantification for IL-6, i.e. 0.6pg/ml, so will not be considered further. 
Following dialysis and filtration only CR34 showed an increase in IL-8 levels and CR42, 
CR47, CR38 and CR45 now showed a significant decrease in IL-8 levels (Table 17). 
CR34 after dialysis and filtration contains 75 µmol/l bile acids, reduced from 1247 µmol/l 
and did not contain any measured pathogens.  It appears that whatever was producing the 
stimulation is not removed by dialysis so must have molecular weight larger than 10 – 
14kDa but is not as large as bacteria which would be removed by filtration (0.22µm). The 
significant decrease in IL-8 levels compared to basal levels is more difficult to explain. 
One possibility is that the juice contains stimulatory and inhibitory factors, the 
stimulatory factors are removed by dialysis and filtration but the inhibitory factors 
remain. There is also a general down regulation of IL-6 and GMCSF by the dialysed and 
filtered juices but as explained above the changes are too small to be considered.   
The mixture of bile acids had no effect on IL-8 and GMCSF production but showed a 
significant increase in IL-6 production.  However the median basal level of 5.4pg/ml is 
calculated from only two measurements, compared to the bile acid stimulation median of 
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6.4pg/ml calculated from 14 measurements. In addition the difference of 1.1pg/ml is close 
to the limit of accurate quantification so will not be considered further. 
When the HT-29 MTX goblet cells were stimulated with individual primary and 
secondary bile acids, porcine pepsin, different gastric juices (whole, filtered and dialysed) 
samples and a bile acid mixture, there was no significant effect on cell viability as 
measured by CellTiter- Blue cell viability assay (Promega. Madison).  
From these experiments it appears that the goblet cells have a similar phenotype to PBEC 
in that they basally secrete high levels of IL-8 and very low levels of GMCSF and IL-6 




5.4.1 IL-8, IL-6 and GM-CSF levels, after goblet cell stimulation with 




























Figure 59: The effect of stimulating goblet cell HT-29 MTX with chenodeoxycholic acid 
and its effect on IL-8 release, following stimulation for 48 hours. Cytokine secretion in 
cell supernatants was measured by MSD ELISA. P values of 0.05 or less were regarded 







































Figure 60: The effect of stimulating goblet cell HT-29 MTX with chenodeoxycholic acid 
and its effect on IL-6 release, following stimulation for 48 hours. Cytokine secretion in 
cell supernatants was measured by MSD ELISA. P values of 0.05 or less were regarded 






























Figure 61: The effect of stimulating goblet cell HT-29 MTX with chenodeoxycholic acid 
and its effect on GMCSF release, following stimulation for 48 hours. Cytokine secretion 
in cell supernatants was measured by MSD ELISA. P values of 0.05 or less were regarded 





5.4.2   IL-8, IL-6 and GM-CSF levels, after goblet cell stimulation with the 


























Figure 62: The effect of stimulating goblet cell HT-29 MTX with doxeycholic acid and its 
effect on IL-8 release, following stimulation for 48 hours. Cytokine secretion in cell 
supernatants was measured by MSD ELISA. P values of 0.05 or less were regarded as 




































Figure 63: The effect of stimulating goblet cell HT-29 MTX with doxeycholic acid and its 
effect on IL-6 release, following stimulation for 48 hours. Cytokine secretion in cell 
supernatants was measured by MSD ELISA. P values of 0.05 or less were regarded as 



























Figure 64: The effect of stimulating goblet cell HT-29 MTX with doxeycholic acid and its effect 
on GMCSF release, following stimulation for 48 hours. Cytokine secretion in cell supernatants 
was measured by MSD ELISA. P values of 0.05 or less were regarded as significant. The results 







5.4.3    IL-8, IL-6 and GM-CSF levels, after goblet cell stimulation with the 































Figure 65: The effect of stimulating goblet cell HT-29 MTX with lithocholic acid and its 
effect on IL-8 release, following stimulation for 48 hours. Cytokine secretion in cell 
supernatants was measured by MSD ELISA. P values of 0.05 or less were regarded as 



































Figure 66: The effect of stimulating goblet cell HT-29 MTX with lithocholic acid and its 
effect on IL-6 release, following stimulation for 48 hours. Cytokine secretion in cell 
supernatants was measured by MSD ELISA. P values of 0.05 or less were regarded as 





























Figure 67: The effect of stimulating goblet cell HT-29 MTX with lithocholic acid and its 
effect on GMCSF release, following stimulation for 48 hours. Cytokine secretion in cell 
supernatants was measured by MSD ELISA. P values of 0.05 or less were regarded as 







5.4.4 IL-8, IL-6 and GM-CSF levels, after goblet cell stimulation with Pepsin at  
37 ºC pH7.4 for 48hours in 10% CO2. 
 
  



















Figure 68: The effect of stimulating goblet cell HT-29 MTX with porcine pepsin and its 
effect on IL-8 release, following stimulation for 48 hours. Cytokine secretion in cell 
supernatants was measured by MSD ELISA. P values of 0.05 or less were regarded as 



























Figure 69: The effect of stimulating goblet cell HT-29 MTX with porcine pepsin and its 
effect on IL-6 release, following stimulation for 48 hours. Cytokine secretion in cell 
supernatants was measured by MSD ELISA. P values of 0.05 or less were regarded as 
significant. The results shown are median values from experiments, n=4. 
 






















Figure 70: The effect of stimulating goblet cell HT-29 MTX with porcine pepsin and its 
effect on GMCSF release, following stimulation for 48 hours. Cytokine secretion in cell 
supernatants was measured by MSD ELISA. P values of 0.05 or less were regarded as 




5.4.5 IL-8, IL-6 and GM-CSF levels, after goblet cell stimulation with whole human 




























Figure 71: The effect of stimulating the goblet cell line HT-29 MTX with whole gastric 
juice and its effect on IL-8 release, following stimulation for 24 hours. Cytokine secretion 
in cell supernatants was measured by MSD ELISA. P values of 0.05 or less were regarded 
as significant.  The results shown are median values from experiments, n= 6. 
 
 






p=0.06 p=0.31 p=0.03 p=0.03 p=0.03 p=0.43 p=1 p=0.56










Figure 72: The effect of stimulating goblet cell HT-29 MTX with whole gastric juice and 
its effect on IL-6 release, following stimulation for 24 hours. Cytokine secretion in cell 
supernatants was measured by MSD ELISA. P values of 0.05 or less were regarded as 











 whole gastric juice patients 1:1000 
LTx8 CR42 CR47 CR52 CR34 CR38 CR50 CR45 
IL-8  * ___  *  *  *  *  *  * 
IL-6 ___ ___ ___ ___ ___ ___ ___ ___ 
GMCSF ___ ___ ___ ___ ___ ___ ___ ___ 
 
Table 18: The whole gastric juice patients challenge for the goblet cell line HT-29 MTX, which 
demonstrated significant stimulation of cytokine release.  
  Increase 



























5.4.6 IL-8, IL-6 and GM-CSF levels, after cell stimulation with filtered and dialysed 






























Figure 73: The effect of stimulating goblet cell HT-29 MTX with filtered and dialysed 
sed gastric juice and its effect on IL-8 release, following stimulation for 24 hours. 
Cytokine secretion in cell supernatants was measured by MSD ELISA. P values of 0.05 
or less were regarded as significant. The results shown are median values from 












































Figure 74: The effect of stimulating goblet cell HT-29 MTX with filtered and dialysed 
gastric juice and its effect on IL-6 release, following stimulation for 24 hours. Cytokine 
secretion in cell supernatants was measured by MSD ELISA. P values of 0.05 or less 
were regarded as significant. The results shown are median values from experiments, 




































Figure 75: The effect of stimulating goblet cell HT-29 MTX with filtered and dialysed 
gastric juice and its effect on GMCSF release, following stimulation for 24 hours. 
Cytokine secretion in cell supernatants was measured by MSD ELISA. P values of 0.05 
or less were regarded as significant. The results shown are median values from 






Table 17:  the diluted whole patient gastric juice filtered and dialised which 
demonstrated a significant effect on cytokine release. 
 
 
 whole gastric juice patients 1:1000 
LTx8 CR42 CR47 CR52 CR34 CR38 CR50 CR45 
IL-8 ___ * * ___ * * ___ * 
IL-6 ___ * * ___ * ___ * * 
GMCSF ___ * * ___ * * ___ * 
 
Table 19: The whole gastric juice (1:1000) challenge for goblet cell HT-29 MTX, which 
demonstrated significant changes to cytokine release.  
  Increase 


























5.4.7 Comparison IL-8, IL-6 and GM-CSF levels, after cell stimulation with whole, 













Whole diluted gastric juice












Figure 76: The effect of stimulating goblet cell HT-29 MTX with whole, filtrated and dialysed 
human gastric juice at the same 1:1000 dilution, its effect on IL-8 release, and cytokine secretion 
in cell supernatants was measured by MSD ELISA. The results shown are mean & SEM values 










Whole diluted gastric juice










Figure 77: The effect of stimulating goblet cell HT-29 MTX with whole, filtrated and dialysed 
human gastric juice at the same 1:1000 dilution, its effect on IL-6 release, and cytokine secretion 
in cell supernatants was measured by MSD ELISA. The results shown are mean & SEM values 










Whole diluted gastric juice














Figure 78: The effect of stimulating goblet cell HT-29 MTX with whole, filtrated and dialyses 
human gastric juice at the same 1:1000 dilution, its effect on GMCSF release, and cytokine 
secretion in cell supernatants was measured by MSD ELISA. The results shown are mean & SEM 





5.4.8 IL-8, IL-6 and GM-CSF levels, after goblet cell stimulation with a bile acid 






















Figure 79: The effect of stimulating goblet cells HT-29 MTX with bile acids mixture, its effect on 
IL-8 release, following stimulation for 48 hours. Cytokine secretion in cell supernatants was 
measured by MSD ELISA. P values of 0.05 or less were regarded as significant.The results shown 
































Figure 80: The effect of stimulating goblet cells HT-29 MTX with bile acids mixture, its effect on 
IL-6 release, following stimulation for 48 hours. Cytokine secretion in cell supernatants was 
measured by MSD ELISA. P values of 0.05 or less were regarded as significant.The results shown 

























Figure 81: The effect of stimulating goblet cells HT-29 MTX with bile acids mixture, its effect on 
GMCSF release, following stimulation for 48 hours. Cytokine secretion in cell supernatants was 
measured by MSD ELISA. P values of 0.05 or less were regarded as significant.The results 




Goblet cells are important cells of the airway in health and disease. However the source 
of the HT29-MTX cells used in my experiments must be considered, as these goblet cells 
are an immortalised cell line derived from those of the human colon. Unlike goblet cells 
of the colon, which biosynthesise and secrete MUC2 these goblet cells act like those of 
the airways in their secretion of MUC5AC and MUC5B (Smirnova et al., 2002). The fact 
that these cells are acting atypically may suggest that the stimulation data derived from 
them is non-physiological and can only provide an indication of in vivo situation. It could 
also be considered that these cells, being derived from an environment where bile and 
other gastric contents are common place, are innately resistant to damage or stimulation 
by such components. This is confirmed by the lack of any changes in cell viability. It has 
previously been shown that IL-8 regulates mucin gene expression in lung epithelial 
tissues in vitro (Bautista et al., 2009).In the HT29-MTX cell linethe Newcastle group has 
previously shown that IL-8 upregulated the secretion of MUC5AC and MUC5B mucins 
in a concentration-dependent manner, with a maximum response at an IL-8 concentration 







































6.1 General Discussion 
 
For patients with a variety of end stage lung diseases, lung transplantation has become an 
effective therapy, however, the development of post transplant bronchiolitis obliterans 
remains a major limitation to the long-term success of this process. Bronchiolitis 
obliterans (i.e. a process of obliteration of the small airways) and its clinical correlate the 
bronchiolitis obliterans syndrome (BOS, identified as a persistent drop in the forced 
expiratory volume in 1 second post transplantation) can rapidly develop and has a poor 
response to augmented immunosuppression. This accounts for more than 30% of all 
deaths occurring after the third post operative year (Burke et al., 1984, Boehler et al., 
1998). Associations between BOS severity and time to first appearance of BOS and bile 
acid aspiration, alveolar neutrophilia and IL-8 have also been reported (D'Ovidio et al., 
2005b). The bronchoalveolar lavage fluid obtained from patients with BOS contains bile 
acids that would appear to be a marker of retrograde aspiration (D'Ovidio et al., 2005b). 
The underlying cause of bronchiolitis obliterans are poorly understood; although 
alloimmune-mediated injury directed against endothelial and epithelial structures are 
thought to be the major culprit, non-alloimmunologic inflammation, including viral 
infections or ischemic injury have also been implicated  to have a major role (Estenne et 
al., 2002). Amongst other possible inflammatory conditions, it is thought that aspiration 
secondary to gastroesophageal reflux (GOR) can contribute to lung allograft dysfunction 
and lead to possible development of bronchiolitis obliterans (Berkowitz et al., 1995, 
Davis et al., 2003b). Consequently whether or not GOR and aspiration in lung transplant 
patients predicts the development of BOS needs further investigatation. GOR after lung 
transplantation may be promoted due to the potential for vagal nerve injury during the 
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course of transplantation and later on because of the effects of immunosuppressive drugs 
such as calcineurin inhibitors (cyclosporine and tacrolimus) that prolong gastric emptying 
(Berkowitz et al., 1995, Young et al., 2003). The association between lung disease and 
GOR has been suspected for a considerable time (Pearson and Wilson, 1971, Belsey, 
1979, D'Ovidio et al., 2005b). In fact, GOR prevalence within patients with a variety of 
lung diseases has been documented in many instances, for example, patients with asthma, 
cystic fibrosis (CF), and idiopathic pulmonary fibrosis (Feigelson et al., 1987, Tobin et 
al., 1998) have been shown to have abnormal levels of GOR. In addition, GOR has also 
been associated with the development of bronchiolitis obliterans and pneumonia (Sadoun 
et al., 1988). Pathophysiological studies of chronic respiratory diseases such as chronic 
cough (Irwin et al., 1981, Sifrim et al., 2005) , cystic fibrosis (Feigelson and Sauvegrain, 
1975, Blondeau et al., 2008a), and asthma (Rosztoczy et al., 2008, Harding, 2001) have 
found gastroesophageal reflux GOR to be a potential common instigator. Increased GOR 
after lung transplantation (LTx) can also contribute to the development of chronic 
rejection or bronchiolitis obliterans syndrome (BOS) (Blondeau et al., 2008b, D'Ovidio et 
al., 2006a, Palmer et al., 2000, Young et al., 2003). Ciliated and nonciliated airway 
epithelial cells can be damaged by exposure to gastric contents (Ohrui et al., 1997, 
Wynne et al., 1981) (Harding, 2001, Blondeau et al., 2008b, D'Ovidio et al., 2006a). 
Aspirated gastric contents cause impairment of mucociliary transport and are associated 
with the colonization of microorganisms in airways (Zeiher and Hornick, 1996, D'Ovidio 
et al., 2006a). Besides the lung injury, acid aspiration also induces the production of an 
inflammatory cytokine, IL-8 as measured in alveolar and bronchoalveolar lavage fluid 
(Zeiher and Hornick, 1996). It is known that children and adults suffering with CF have 
abnormally high levels of reflux (Ledson et al., 1998, Cucchiara et al., 1991, Blondeau et 
al., 2008a). Furthermore, there is increasing acceptance that clinically hidden, non-acidic 
reflux and aspiration could be an important source of lung injury (Blondeau et al., 2008a). 
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A duodeno-gastro-oesophageal refluxate is more likely to be non-acidic due to the 
neutralising effects of duodenal contents and potentially contains bile acids which have a 
wide range of biological actions.   
Primarily bile acids are involved in the digestion of fat (Kullak-Ublick et al., 2004, 
Lefebvre et al., 2009). Produced from cholesterol by the liver, primary bile acids consist 
of cholate and chenodeoxycholate. Water-soluble conjugates are formed when these 
primary bile acids couple with the amino acids taurine or glycine. Bile acids are actively 
reabsorbed during movement through the ileum and efficiently recycled to the liver. 
Formation of secondary bile acids results from the enzymatic modification of remaining 
primary bile acids by gastrointestinal bacteria. Hence, chenodeoxycholic acid leads to 
lithocholic acid and cholic acid is converted to deoxycholic acid due to 7α-dehydroxylase 
activity possessed by intestinal bacteria (Kullak-Ublick et al., 2004, Lefebvre et al., 2009, 
Setchell et al., 1985).   
 My studies have shown that IL-8, IL-6 and GMCSF release is significantly increased by 
primary (chenodeoxycholate) and secondary (deoxycholate and lithocholate) bile acids 
when PBECs from lung transplantation recipients and CF PBECs are challenged. The 
levels at which bile acids have the effect an these cytokines is within the range that the 
bile acids have been measured in the circulation of children with CF i.e. 0.2 to 0.8 µmol/l 
(Setchell et al., 1985).  
In terms of constitutive production of cytokines there was no difference between non-CF 
PBECs and the CF PBECs. This results differs from the report of Sutanto et al, where 
they reported that CF airway cells from children produced greater amounts of IL-6 than 
airway cells from from healthy children with mean levels of 6000 pg/ml/10
6
 cells and 250 
pg/ml/10
6
 cells respectively (Sutanto et al., 2011). In the studies presented in this thesis 





 cells.  Normalising the data to 10
6
 cells gives 650 pg/ml and 375 
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pg/ml respectively.  This is higher than the normal pediatric airway epithelial cells (AEC) 
but much lower than the CF pediatric cells.  This high level of constitutive IL-6 
production is also a characteristic of AECs from children with asthma (McNamara et al., 
2008). Some of the differences could be related to the cells used in this thesis, because 
they are adult.  In addition the CF cells are from end stage lungs at the time of 
transplantation, where the patient has been subject to life long infections and anti 
microbial treatments. This compares with studies in paediatric patients with a median age 
of 4.1 years and no evidence of P. aeruginosa infections and consequently a much lower 
exposure to infection / antibiotic treatment. Both Non CF PBECs and CF PBECs have 
high levels of constitutive IL-8 production with mean basal levels of 3000 pg/ml/4x10
5
 
cells and 2500 pg/ml/4x10
5
 cells respectively, showing IL-8 production is about 10 times 
higher than IL-6 and GMCSF. In terms of the cytokines measured both these types of 
PBECs have an IL-8 phenotype unlike the pediatric AECs which have an IL-8/IL-6 
secreting phenotype (Sutanto et al., 2011). 
 
My study using  CF lung derived cells and brushings from lung transplant patients has 
shown that IL-8 release from CF PBECs was stimulated by low levels of all the 
individual bile acids used, 0.25 µmol/l and above. Non-CF PBECs do not respond until  
1µmol/l. As tables 18 and 19 shows CF PBECs respond to bile acid challenge with a 
lower threshold than PBECs from lung transplant recipients. This increased 
responsiveness may be explained by the fact that these PBEC samples are brushings from 
transplanted (healthy) lungs where patients use immunosuppressant drugs, however CF 
PBECs samples are produced by enzymatic dysaggregation and scraping from end stage 




CF PBECs were not stimulated to produce IL-6 or GMCSF until 1 µmol/l bile acids. In 
the non-CF PBECs IL-6 productions was not stimulated until 5µmol/l with GMCSF 






Bile acids Chenodeoxycholic acid Deoxycholic acid Lithocholic acid  
Bile acids 
conc µmol/l 
0.25 0.5 0.75 1 5 10 0.25 0.5 0.75 1 5 10 0.25 0.5 0.75 1 5 10 







































































Table 20: The effect of different levels of bile acids on PBECs from explanted Cystic Fibrosis 
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Table 21: The effect of different levels of bile acids on PBECs from lung transplant recipient 48 




There is limited research relating to the characterisation of bile salts in the lung and in 
particular in advanced CF lung disease. Recently a detailed study of aspiration injury in 
patients with ventilator-associated pneumonia has reported the detection of lithocholic 
acid in the lung at a mean (SEM) concentration of 2.8 ± 0.6 µmol/l (Wu et al., 2009). The 
elevated levels of bile acids were linked with lung injury and were higher when compared 
to patients ventilated but without pneumonia.  The study by Wu et al. is comparable and 
supportive of the approach used in my research. The research by Wu et al. evaluated the 
effect of bile acid challenge on cultured alveolar epithelial cells and concluded that 
chenodeoxycholic acid challenge led to IL-8 generation at the message and protein level. 
The increase in IL-8 production was demonstrated to be via activation by phosphorylation 
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of a p38 MAP kinase pathway, as the IL-8 up regulation was inhibited by dexamethasone 
and the selective p38 inhibitor SB203580 (Wu et al., 2009). The fact that the bile acids 
act via a phosphorylation pathway is not surprising, in that bile acids have been shown to 
be regulating molecules.  Bile acids activate cell signalling pathways, c-jun N terminal 
kinase 1/2, AKT and ERK 1/2 in epithelial cells of the gut (Hylemon et al., 2009) 
The formation, secretion and re-absorption of bile acids take place under precise control 
(Raufman et al., 2003). Retention of bile acids through homeostatic mechanisms includes 
active, receptor-mediated uptake in the duodenum and ileum through the apical sodium 
dependent bile acid transporter, coupled with the enterohepatic circulation. Therefore, in 
the normal situation less than 5% of bile acids are excreted (Kullak-Ublick et al., 2004, 
Lefebvre et al., 2009). However, in CF extraction of bile acids can be impaired at both 
intestinal absorption and hepatic levels because of, dysregulated lipid metabolism 
(Brodlie et al.) and overall compromised liver function (O'Sullivan and Freedman, 2009, 
Ratjen, 2009). Children with CF have higher faecal excretion of bile acids; CF patients 
with pancreatic insufficiency have been reported with bile acid malabsorption (Setchell et 
al., 1985). It is possible that the complexity of bile acid profiles in CF may occur due to 
lifelong antibiotic treatment. This may have the result of disturbing the normal 
homeostatic gastrointestinal bacterial populations, responsible for producing secondary 
bile acids (Kullak-Ublick et al., 2004, Lefebvre et al., 2009). Due to the fact that CF 
involves (O'Sullivan and Freedman, 2009) disordered bile homeostasis, (Setchell et al., 
1985)  duodeno-gastro-oesophageal reflux, (Sweet et al., 2009, Fathi et al., 2009) and 
aspiration; it may best be regarded as a disease that involves both the respiratory and 
gastrointestinal tract (Blondeau et al., 2008a, D'Ovidio et al., 2006a). Within this broader 
paradigm, aspiration of refluxate may be an under recognised contributor to airway injury 
in CF (Appel et al., 2007). Epithelial injury has long been suspected to have a connection 
with bile acids. For example, Barrets’ oesophagus is considered to be a potentially pre-
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cancerous lesion, denoted by epithelial injury linked to bile acid reflux (Sital et al., 2006). 
Similarly, post-lung transplantation lung injury could be caused by bile acid aspiration 
(Blondeau et al., 2008a, D'Ovidio et al., 2006a) with potential mechanisms involving 
disruption of surfactant and overall innate immunity (D'Ovidio et al., 2006a). Work 
associated with my research has identified both primary and secondary bile acids at levels 
similar to, or greater than those shown in ventilator-associated aspiration pneumonia.  The 
range of chenodeoxycholic acid concentration was 1.5 to 5.3µmol/l and lithocholic acid 
was 2.8 ± 0.6µmol/l (Wu et al., 2009). I have therefore evaluated the effect of levels of 
chenodeoxycholic acid, deoxycholic acid and lithocholic acid on PBECs at levels which 
can occur in CF lung disease. Cell viability for PBECs and CF PBECs are affected by low 
concentrations of lithocholic acid 5µmol/l but not with the other bile acids used at this 
concentration.  
Bile acid molecules are predominantly ampipathic structures, having a wedge like 
molecular shape (Resarcher, 2008). They have a steroid part which is hydrophobic in 
character, and a hydrophilic side represented by the hydroxyl group (Hofmann, 1999a). 
The intrinsic toxicity profile of the bile acids may well be linked to their hydrophobicity, 
as the more hydrophobic bile acids have been found to be more toxic. On the other hand, 
the hydrophobicity has an inverse relationship with the number of OH groups. Therefore, 
the highly hydrophobic and highly toxic lithocholic acid has only one OH group, 
whereas, decreasing hydrophobicity and decreasing toxicity can be observed in 
deoxycholic acid and chenodeoxycholic acid with two OH groups (Resarcher, 2008). 
Mucosal cell membranes may be damaged by the cytotoxic effects of bile acids. In fact, 
many tissues may be adversely affected, both intra- and extra cellularly. Lithocholic acid 
is a highly toxic substance produced in the body, and is known for its carcinogenic 
properties. Lithocholic acid enters the liver where it is either sulphated or esterified to 
glucuronic acid and then excreted (Resarcher, 2008). The toxic effect of lithocholic acid 
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on PBECs is shown in Figures 6 (E) and 6 (D) with 200µmol/l and 50µmol/l 
concentrations for lithocholic acid. This is in agreement with Wu et al., (2009) where 
human alveolar epithelial cells become detached and floated with chenodeoxycholate 
levels of over 40 µmol/l (Wu et al., 2009). Concentrations of chenodeoxycholate above 
10µmol/l cause cell death with 25µmol/l causing 50% cell death. Concentrations of 
1µmol/l or above for deoxycholate and lithocholate affect cell viability of PBECs, 
however the effect is variable, for example 25µmol/l of chenodeoxycholic acid causes 
83% cell death, but with lithocholic acid the effect on cell viability starts at concentration 
above 5µmol/l lithocholic acid where 45 % of PBECs cells are dead and at 25 µmol/l 
80% of the cells are dead. 
Throughout this study the production of cytokines and growth factors by PBECs from 
lung transplantation recipients and CF PBECs was evaluated, concentrating on cytokines 
known to be implicated in airway inflammation and remodelling common to CF and 
BOS. Pathophysiological studies of CF have implicated IL-8 and IL-6 (Dufresne et al., 
2009). IL-8 is a neutrophil chemokine and mediator of vascular remodelling (Walters et 
al., 2008). Increased levels of IL-8 and neutrophils are a distinctive presentation of the CF 
airway. This inflammation is part of the early stage of CF lung disease, with research 
showing increased levels can occur before bacterial colonisation and infection (Balough 
et al., 1995). It is relevant to point out that IL-8 is a mucin secretagogue (Smirnova et al., 
2002, Smirnova et al., 2001) given that accumulation of mucus in neutrophilic 
inflammation is also a key element in CF lung pathophysiology. GMCSF, a growth factor 
that can regulate both the accumulation and the activity of neutrophils was also produced 
as a direct outcome of bile acid stimulation of PBECs. Based on my data, neutrophilic 
inflammation, tissue remodelling (Walters et al., 2008) and mucus hyper-secretion 
(Smirnova et al., 2002, Smirnova et al., 2001) can be attributed as potential consequences 
of lung injury following bile acid aspiration. Due to the fact that reflux and potential 
150 
 
aspiration has previously been documented in paediatric and adult populations, it would 
be plausible to treat it as a chronic contributor to lung damage in CF (Blondeau et al., 
2008a, Brodzicki et al., 2002, Button et al., 2005, Gustafsson et al., 1991, Heine et al., 
1998, Ledson et al., 1998, Malfroot and Dab, 1991, Scott et al., 1985, Vic et al., 1995). In 
work connected with this study my research group has demonstrated that the lungs of 
people with advanced CF lung disease removed at the time of transplantation contained 
significant levels of bile acids, lithocholic acid concentrations ranged between               
0.6-25.2µmol/l. These levels detected were used to inform the challenge of cultured 
airway epithelial cells from explanted CF patients. The results of these experiments have 
indicated that an increase in the release of the key inflammatory mediators IL-8 and IL-6 
has been caused by physiologically achievable levels of individual primary and secondary 
bile acids. With the non-CF PBECs if one compares the maximal response for IL-8 in 
terms of fold increase above basal, the chenodeoxycholate (CD) deoxycholate (DC) and 
lithocholate (LC) produce 3.75, 7.6, and 8.9 fold increase in output (by comparing the 
basal median to the highest median output at any bile acid concentration). Demonstrating 
lithocholate has the biggest inflammatory effect. Doing the same calculation for IL-6 and 
GMCSF shows IL-6 levels are stimulated by 4 (CD), 2.9 (DC) and 3.4 (LC) fold and 
GMCSF by 2.3 (CD), 2.3 (DC), and 54 (LC) fold. Again showing that lithocholate is a 
powerful inflammatory stimulant particularly for GMCSF. 
In the case of CF PBECs, the fold increase for IL-8 were 4 (CD), 5 (DC), and 8 (LC), for 
IL-6 1.32 (CD), 5.3 (DC), and 2.9 (LC), for GMCSF 4 (CD), 2 (DC), and 14 (LC). 
Demonstrating that the CF cells respond most to lithocholate.  
When PBECs and CF PBECs were challenged with porcine pepsin at pH 7.4 there was no 
effect on PBECs and CF PBECs in vitro levels of IL-8 IL-6 and GMCSF. This conclusion 
was also supported by another study which showed no association between pepsin 
concentration and IL-8 production (Mertens et al., 2010) . At a low pH pepsin may well 
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be able to cause some damage to the connective tissues and extracellular matrix of the 
lung tissues in vivo pepsin will be denatured at pH 7.2  consequently the data presented 
here are for inactive pepsin.  
In addition a bile acid mixture had no effect on the PBECs and CF PBECs in terms of 
release of any significant levels of cytokines. The bile acid mixture was made up in 
composition and concentrations of bile salts as close as possible to those present in human 
bile (50% taurocholic acid, 15% taurodeoxycholic acid, 30% chenodeoxycholic acid and 
5% lithocholic acid) so 65% are conjugated. Conjugation may be important in the effect 
of produced (Hofmann, 2004), in that there will be an association between structure of the 
bile acid and effects on transepithelial secretory responses. It is difficult to explain why 
the bile acid mixture does not cause up regulation of cytokine production, as the mixture 
contains the free bile acid chenodeoxycholate at a concentration of 3µmol/l. This 
concentration would also stimulate IL-8, IL-6 and GMCSF production from PEBCs. The 
mixture is 65% (65µmol/l) conjugated bile acids which are much less hydrophobic 
compared to the free bile acids. Wu et al., reported that conjugated bile acids do not 
stimulate IL-8 production at concentration of 10 µmol/l from human alveolar cells (Wu et 
al., 2009). In addition chenodeoxycholate was five times more potent in up regulating 
prostaglandin synthesis in oesophageal squamous cells (Zhang et al., 2001). It has not 
been reported how PBECs react to bile acid mixtures containing both conjugated and 
non-conjugated bile acids but one could speculate, based on large differences in effect 
that they may antagonise each other leading to no increase in cytokine production. 
As with the bile acid stimulation experiments the CF PBECs were more responsive to 
gastric juice samples than the PBECs. With only two out of eight juices stimulating 
production of IL-8 from non CF PBECs compared to four out of eight with the CF 
PBECs. In terms of IL-6 up regulation only one juice was effective with the PBECs 
compared to three out of eight with the CF PBECs. Interestingly the gastric juice has little 
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effect on GMCSF levels. In addition there was marked variability in the levels of the cells 
response to the gastric juice. 
When the gastric juice was filtered, the stimulatory effect was abolished with both CF and 
non-CF cells, suggesting that the major inflammatory signals had been removed. In the 
same cases the molecules responsible would appear to be bile acids and in others 
pathogens or a mixture of the two. Pepsin did not seem to have a direct role. The variation 
in response could be pathogen species related as demonstrated by Stathopoulou et al., 
(2010) who showed that IL-6 levels produced by human gingival epithelial cells was 
significantly higher with F. nucleatum compared to S. gordonii (Stathopoulou et al., 
2010). Also Sutanto et al., (2011) showed that CF airway cells responded to human 
rhinovirus with a marked increase in IL-8 compared to non-CF cells (Sutanto et al., 
2011). So it seems pathogen type and cells type may play a role in the cytokine response. 
The goblet cells line produced a similar basal output of IL-8 as the PBECs i.e. ~3000 
pg/ml, but the output of IL-6 and GMCSF was less than 10 pg/ml.  These levels for IL-6 
and GMCSF are approximately 20 times lower than the PBECs basal output. The goblet 
cell line has a constitutive IL-8 phenotype in agreement with Smirnova et al (Smirnova et 
al., 2002). These cells have a resistance to bile acids unlike the PBECs.  
The goblet cell line did not release significantly increased levels of IL-8 when exposed to 
seven out of eight of the gastric juice samples. The stimulation effects of the gastric juice 
on goblet cells needs to be considered with some caution as the basal output of IL-8 in the 
whole gastric juice was only 25 pg/ml and the highest stimulated levels were around  
300pg/ml, whereas the basal output in the experiments with filtered and dialysed juices 
was 975pg/ml. Both these basal levels are much lower than the basal level for the bile 
acid stimulation experiments. Suggesting the cells was behaving abnormally although 
there were no overt signs of cell death or infection. Taken overall the results with the 
goblet cells, assuming we can consider them as representative of airway goblet cells, 
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would imply that IL-6, GMCSF driven inflammatory process instigated by reflux and 
aspiration, will not be added to by the goblet cells.  
The data presented in this thesis showing the potential for reflux/aspiration containing 
bile acids to cause damage to the CF lung pre and post transplantation, produces further 
evidence supporting the need for for clinical and surgical interventions to prevent lung 
damage associated with reflux 
The macrolide antibiotic Azithromycin has been documented as having positive effects 
on gastric motility (Larson et al., 2010), which may be beneficial in reflux associated 
injury. Recent reports have suggested that azithromycin treatment can prevent damage to 
transplanted lungs and in some cases reverse the development of BOS (Yates et al., 2005, 
Gerhardt et al., 2003a). In addition a single centre trial (double-blind randomised 
controlled) showed that over a two year period patients receiving azithromycin had  a 
significantly lower incidence of BOS compared to placebo, 12.5% versus 44.2% and that 
patients on azithromycin had a better BOS-free survival time (Vos et al., 2011). However, 
overall survival time was not different between the groups. This suggests that whatever is 
damaging the lungs is not completely dealt with by azthromycin treatment. 
It is therefore possible that some level of reflux/aspiration persists on azithromycin 
treatment even though azthromycin should reduce reflux/aspiration because of its pro-
motile effect on the gut (Larson et al., 2010). In fact Mertens et al 2011 present evidence 
that transplant patients that have measurable bile acids in their BAL had reduced survival 
time and faster decline in FEV1 and progression of BOS compared to those without bile 
acids, even when undergoing azithromycin treatment. 
Consequently it would seem that further methods to stop reflux need to be employed such 
as fundoplication even when azthromycin therapy is applied. Although this dual therapy 
would only need to be applied when evidence of bile acid aspiration is available and can 




6.2 Overall Conclusion  
 
To conclude the work done in this project, a success rate of 70% in culturing primary 
bronchial epithelial cells, from both lung transplantation recipients and explanted lungs 
for cystic fibrosis patients was achieved. However the success rate was 85% with the 
goblet cell line HT-29 MTX. 
PBECs from lung transplant patients had different responses to stimulation shown by  
IL-8, IL-6 and GMCSF production after treatment by individual primary and secondary 
bile acids, using concentrations for the bile acids 1µmol/l and above.  
CF PBECs were able to release significantly stimulated levels of IL-8 after treatment by 
all the bile acid concentrations including the lowest concentration 0.25µmol/l. However, 
the CF PBECs are similar to transplant PBECs in terms of IL-6 and GMCSF stimulation, 
in that bile acid concentrations of 1µmol/l and above were required. 
The cells used in this study did not increase the levels of IL-8, IL-6 and GMCSF released 
after treatment by porcine pepsin and a bile acid mixture as shown in section (2.2.5). 
The different human gastric juice preparations evaluated (whole, filtered and dialysed) 
samples regulated the cells to release significant levels (increased / decreased) depending, 
on the gastric juice content as (Table 9). 
The goblet cell line HT-29 MTX are resistant to bile acids, and did not release any 
significantly increased levels of IL-8, IL-6 and GMCSF after exposure to porcine pepsin 
and a bile acid mixture at concentrations as shown in section (2.2.5) but were stimulated 
with gastric juice.  
As a result from this work I recommend that bile acid assessments should be made in lung 
samples as a regular test for the patients who have had lung transplantation and especially 
those transplanted for cystic fibrosis disease. CF patients may well go on to have elevated 
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levels of bile acids in the new lungs considering the CFTR related defects in bile acid 
transport. My data indicate that high concentrations of bile acids are toxic for the 
transplant PBECs and CF PBECs, but lithochlic acid at 5µmol/l and above is the most 






6.3 Future Directions for Research  
 
 As we can see in this study 30% of lung transplantations in our local hospital are for 
cystic fibrosis and the results show that significant stimulated levels of IL-8, IL-6 and 
GMCSF are released from cystic fibrosis primary bronchial epithelial cell CF PBECs 
after stimulation by bile acids and gastric juice. 
 In future studies we could use more cystic fibrosis patient samples for additional 
studies; we can use CF PBECs samples from explants and lung transplantations, 
studying the same patients’ pre and post lung transplantation. In particular it 
would be useful to carry out a longitudinal study of bile acid levels with time in 
the newly transplantation lung.    
 For the gastric juice studies, future studies could take samples from the same 
patients and analyse these for pathogens, pepsin activity, pH and total bile acid 
levels in the same time the patients have bronchoscopy, six times in the first year 
after transplant.  
  Bile acids should be measured by sensitive methods such as tandem mass 
spectrometry. This is because the lowest level of detection with the colourimetric 
assay is around 5µmol/l. 
 In this study we stimulated the samples with gastric juice for 24 hours so future 
studies could evaluate the effect of 48 hours stimulation with bile acids.  
 For cell viability we can look for more accurate and high quality methods such as 
the methylthiazolyldiphenyl-tetrazolium bromide) assay.  
 As we know it is hard to find enough patients from our local hospital population 
for study. We could in future contact other lung transplantation centres to organise 
multi centre larger studies. 
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 A study should be set up to investigate the possibility that bile acids level in the 
lung is a biomarker which may predict for chronic rejection (using the enhanced 
bile acid measurement technology). 
  Future studies should identify whether bile acids are present in people with CF 
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